ER-localized LULL1 function is required for the abnormal INM concentration of disease-related delta-E torsinA by Holbrook, Kristen Nicole
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
Masters Theses Graduate School
5-2012
ER-localized LULL1 function is required for the
abnormal INM concentration of disease-related
delta-E torsinA
Kristen Nicole Holbrook
kholbrook@tennessee.edu
This Thesis is brought to you for free and open access by the Graduate School at Trace: Tennessee Research and Creative Exchange. It has been
accepted for inclusion in Masters Theses by an authorized administrator of Trace: Tennessee Research and Creative Exchange. For more information,
please contact trace@utk.edu.
Recommended Citation
Holbrook, Kristen Nicole, "ER-localized LULL1 function is required for the abnormal INM concentration of disease-related delta-E
torsinA. " Master's Thesis, University of Tennessee, 2012.
https://trace.tennessee.edu/utk_gradthes/1162
To the Graduate Council:
I am submitting herewith a thesis written by Kristen Nicole Holbrook entitled "ER-localized LULL1
function is required for the abnormal INM concentration of disease-related delta-E torsinA." I have
examined the final electronic copy of this thesis for form and content and recommend that it be accepted
in partial fulfillment of the requirements for the degree of Master of Science, with a major in
Biochemistry and Cellular and Molecular Biology.
Rose E. Goodchild, Major Professor
We have read this thesis and recommend its acceptance:
Andreas Nebenfuehr, Barry Bruce
Accepted for the Council:
Dixie L. Thompson
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)
ER-localized LULL1 function is required for the 
abnormal INM concentration of disease-related delta-
E torsinA 
 
 
 
A Thesis Presented for the 
Master of Science 
Degree 
The University of Tennessee, Knoxville 
 
 
Kristen Nicole Holbrook 
May 2012 
 
  ii 
Copyright © 2011 by Kristen Holbrook 
All rights reserved. 
  iii 
ACKNOWLEDGEMENTS 
 
 
I would like to thank my thesis advisor, Dr. Rose Goodchild, for advice on my 
experimental design and many torsinA related discussions.  Goodchild Lab 
members, especially Dhivya Kumar, have also been a great help in this work. 
Many thanks to my family and friends, who have always supported me.  I would 
like to acknowledge Dr. Andreas Nebenfuehr, Dr. Madhu Dhar, Dr. Howard 
Worman, and Dr. Bill Dauer who kindly supplied some of the reagents that made 
this work possible.  Finally, this work could not have been completed without 
support from the Dystonia Medical Research Foundation and the Tyler’s Hope 
Foundation.   
 
  iv 
ABSTRACT 
 
DYT1 dystonia is an autosomal dominant neurological disease caused by a single amino 
acid deletion in the protein torsinA, resulting in expression of a mutant ΔE [delta E] 
torsinA isoform in DYT1 patients.  Research has consistently found ΔE [delta E] torsinA 
abnormally concentrated in the nuclear envelope (NE) lumen of the endoplasmic 
reticulum (ER), and this has led to the hypothesis NE accumulation of ΔE [delta E] 
torsinA may underlie disease pathogenesis.   
We first investigated where and how ΔE [delta E] NE accumulation occurs.  We found 
that ΔE [delta E] torsinA accumulates at the inner nuclear membrane (INM) NE 
subdomain.  Furthermore, modulating expression of NE-localized interacting partners 
alters NE accumulation of torsinA, but surprisingly, increasing expression of ER resident 
interacting partner LULL1 also leads to torsinA NE concentration.  An ER-localized 
mechanism that promotes the concentration of another ER protein at the NE has never 
been described, so we tested whether LULL1 is functional in the ER.  We used ER-
restricted LULL1 fusion proteins and antibody accessibility assays, and our data reveals 
that there is not an additional subset of LULL1 present in the NE, despite relocalization 
of ΔE torsinA to the INM.    
We broadly tested the relative importance of LULL1 domains.  We co-expressed GFP-
ΔE [delta E] torsinA with LULL1 truncation mutants and found that the torsinA-
interacting luminal LULL1 domain is required to promote ΔE [delta E] torsinA 
accumulation in the NE.  We also find that the cytosolic domain of LULL1 is required for 
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LULL1 function, suggesting that a region other than the torsinA interacting domain 
contributes to the activity of LULL1.  Unexpectedly, we find that dimerization-competent 
heterologous domains can complement for loss of the required LULL1 cytosolic domain.  
Our current focus is the functional significance of LULL1 dimerization in vivo.   
Much of our work has focused on the disease-related torsinA mutant, but very little is 
known about its normal function.  Development of an in vitro system to investigate the 
biochemical cycle of torsinA has proven challenging, but we present the foundation for 
an in vitro system using recombinant torsinA produced in an insect cell based system.   
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CHAPTER 1 : INTRODUCTION 
 
Primary dystonia is estimated to be the third most common movement disorder, but has 
very limited treatment options (1).  DYT1 dystonia is the most severe hereditary primary 
dystonia, characterized by uncontrollable and painful muscle contractions (2).  DYT1 
dystonia is caused by heterozygosity for an in-frame three base pair deletion (Δgag) in 
the TOR1A gene (2), which deletes either of two glutamic acid residues (ΔE 302/3) near 
the C-terminus of the protein torsinA (2).  Mouse models indicate the Δgag deletion is a 
loss-of-function allele, suggesting that TOR1A gene activity is reduced in DYT1 dystonia 
(genotype Δgag/+)(3).  The hypoactive/inactive ΔE protein isoform is expressed in DYT1 
patients, but no other loss-of-function mutations or central nervous system structural 
abnormalities have been identified.  Furthermore, it is unclear whether TOR1A 
haploinsufficiency is the sole underlying cause for DYT1 dystonia, or if the presence of 
the ΔE isoform contributes to disease pathogenesis (4-6).    
Developing a better understanding of the normal function of torsinA, as well as the 
contribution of the ΔE deletion to disease pathogenesis, is critical to the development of 
new therapeutics.  Δgag is the only mutation that causes DYT1 dystonia, which implies 
that the expression of the ΔE isoform could contribute to disease pathogenesis.  There is 
some data that supports the idea that the ΔE isoform is toxic, although there is still no 
proof that the presence of ΔE torsinA plays a role in the disease (7-9).  The effect of ΔE 
torsinA is important to consider, given that reducing ΔE torsinA expression (gene 
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therapy) has been proposed as a treatment for DYT1 dystonia, but this may have no effect 
if ΔE torsinA is not a factor in the disease (10, 11).   
Despite the severity of DYT1 dystonia, little is known about disease pathogenesis.  WT 
torsinA has been consistently described as an endoplasmic reticulum (ER)-resident 
protein, and loss of torsinA function specifically affects the nuclear envelope (NE), a 
continuous subdomain of the ER that borders the nucleus (3, 7, 12-15) (Figure 1.1 A).  A 
specialized subset of proteins is immobilized at the NE (16), and is absent in the bulk ER 
system, so the importance of torsinA function at the NE suggests that its activity is 
directed at an NE-localized partner.  Furthermore, the ΔE isoform abnormally localizes to 
the NE, which has led to the hypothesis that NE-localized ΔE torsinA impairs the normal 
NE function of torsinA and contributes to the pathogenesis of DYT1 dystonia.   
Both torsinA function and ΔE torsinA dysfunction center on the NE, but it is unclear how 
torsinA is targeted to the NE.  The diffusion-retention model describes the classical way 
membrane proteins are targeted to the NE, where NE localization depends on diffusion of 
NE-directed proteins in the continuous ER system until they associate with NE 
immobilized binding partners (Figure 1.1B) (16-20).  The bulk ER system is continuous 
with the NE outer nuclear membrane (ONM), but entrance to the NE inner nuclear 
membrane (INM) is regulated by a size restriction on the cytosolic domain of an INM-
directed protein (Figure 1.1A-B)(16).  The size of torsinA should allow it to access the 
ER/ONM as well as the INM.  The nuclear pore complex (NPC) has been implicated in 
the transport of transmembrane proteins to the INM subdomain of the NE (Figure 1.1B); 
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however, torsinA is peripherally membrane associated, and a solely NPC-directed 
membrane protein transport mechanism remains controversial (16, 20, 21).  
Current research has revealed that ΔE torsinA is expressed in DYT1 dystonia, that 
torsinA function is important in the NE, and that torsinA has multiple interacting partners 
present in both the NE and the continuous ER system (3, 7, 22).  TorsinA is a 
peripherally associated membrane protein, and belongs to the AAA+ (ATPases 
associated with various cellular activities) superfamily of enzymes, which typically form 
multimeric complexes and undergo structural changes as they cycle through nucleotide 
binding, hydrolysis and release (2, 23-26).  These structural changes are transmitted to a 
protein binding partner (the AAA+ substrate) to cause conformational change (23).  
Unbiased studies from multiple research groups have found that torsinA robustly 
interacts with homologous LAP1 and LULL1 membrane proteins, which localize to the 
NE and ER, respectively (8, 22, 27).  Interaction with LAP1 and LULL1 is stabilized by 
AAA+ domain mutations that usually inhibit ATP hydrolysis, such as the Walker Box 
EQ mutation (E171Q torsinA)(5, 22).  Because most AAA+ enzymes interact with their 
substrates in an ATP-bound form, this suggests that both LAP1 and LULL1 are AAA+ 
protein substrates (4).  However, the cellular function of LAP1 and LULL1 remains 
unknown, and several studies have produced conflicting results.  Cellular levels of LAP1 
and LULL1 appear unaffected by loss of torsinA function, a strange result for a AAA+ 
protein substrate (28).  Overexpression of LULL1 targets WT-torsinA to the NE (14), but 
genetic studies have shown that NE-resident LAP1, but not LULL1, is required for 
torsinA function (29).  Furthermore, torsinA has been associated with members of 
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another NE localized complex, the LINC complex, that tethers the nucleus to the 
cytoskeleton(13, 30).   
A recent study found that LULL1 promotes NE accumulation of torsinA, although 
LULL1 remains ER localized, which suggests that LULL1 is not a substrate, but instead 
facilitates torsinA function (14).  However, the effect of LULL1 on ΔE torsinA NE 
accumulation has not been fully addressed.  Both the ΔE deletion and E171Q mutation 
generate NE-localized torsinA, but they have opposite effects on torsinA binding to 
LAP1 and LULL1 (5).  The E171Q mutation stabilizes interaction with both LAP1 and 
LULL1, yet LAP1 and LULL1 do not appear to interact with ΔE torsinA(8).  Therefore, 
it is unclear how the ΔE deletion impairs LULL1 binding, but is targeted to the NE by 
LULL1, which undermines the importance of LULL1 for ΔE torsinA NE targeting (5, 14, 
27).  Furthermore, only a small, but quantitatively significant, reduction in ΔE torsinA 
NE concentration was found after shRNA knockdown of LULL1 expression (14).  
However, the study used a cell system where ΔE torsinA does not clearly mislocalize to 
the NE compared with WT torsinA (14).  It remains unclear whether LULL1 expression 
is important in cell types showing strong ΔE torsinA NE concentration; including 
neurons, the cell type affected by DYT1 dystonia.  Furthermore, although LULL1 seems 
to have a role in torsinA localization, the relative importance of specific LULL1 domains 
is unknown, and the subcellular site of LULL1 ‘activity’ is unclear.  Previous work has 
associated torsinA with other NE resident proteins located in both the INM and ONM 
subdomains of the NE(13, 29, 30).  Although INM resident LAP1 appears to be required 
for WT torsinA function(31), and siRNA reduction of INM resident SUN1 removes both 
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WT and ΔE torsinA from the NE(13), another report associated torsinA with the ONM 
resident nesprin component of the LINC complex(30).  However, we have found that 
siRNA reduction of nesprin levels does not affect ΔE torsinA NE concentration(13).  
Thus, the relative contribution of NE localized interacting partners to the localization of 
ΔE torsinA remains unclear.  
Our current study focuses on developing a better understanding of the torsinA interacting 
partners that affect ΔE torsinA accumulation at the NE.  Our work also centers on 
LULL1, the importance of LULL1 domains, and how an apparently ER-localized protein 
appears to target another ER localized protein to the NE, which will represent the first 
such “targeting” mechanism described.  Finally, we have developed an in vitro system to 
test the normal function of torsinA, its binding interactions, and how function is altered 
by the Δgag deletion.   
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Figure 1.1:The NE-ER System 
A. Schematic shows ER system and the continuous NE subdomain that surrounds the 
nucleus.  Modified from (19) B. Schematic depicting the diffusion retention model of 
membrane protein trafficking to the INM.  Membrane proteins (red bars) are synthesized 
by ribosomes in the main ER system, and diffuse through the ER system, until they reach 
INM binding partners (such as INM localized proteins, lamina, or chromatin) that retain 
them in the INM.  Some reports have implicated the nuclear pore complex (NPC) (shown 
in purple) in the movement of transmembrane proteins to the INM.  Modified from (20)
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CHAPTER 2  : LULL1 TARGETS ΔE TORSINA TO THE INM 
Introduction 
As introduced in Chapter 1, WT torsinA is a luminal, peripherally associated membrane 
protein localized to the bulk ER system, and the disease related ΔE isoform mislocalizes 
to the NE, a subdomain of the continuous ER that surrounds the nucleus (Figure 1.1A).  It 
is unclear whether ΔE torsinA is localized to the luminal membrane face of the 
continuous ER/ONM or to the INM subdomain of the NE.  TorsinA has been associated 
with binding partners in both the ONM and INM subdomains of the NE (13, 22, 30), and 
addressing where ΔE torsinA accumulates can provide clues about how the presence of 
ΔE torsinA might be detrimental to neuronal functioning.  Previous work has suggested 
that INM-localized partner LAP1 is required for WT torsinA function (29).  However, 
knockdown of LAP1 levels does not affect the NE accumulation of ΔE torsinA(13).  
Furthermore, ΔE torsinA has been associated with multiple components of the NE-
spanning LINC complex.  INM-localized LINC component SUN1 is required for ΔE 
torsinA NE concentration(13); other groups have shown that the ONM-localized nesprin 
components of the LINC complex interact with ΔE torsinA(30).  However, we find that 
knockdown of nesprin levels does not affect the NE accumulation of ΔE torsinA(13).  To 
resolve this conflicting evidence, we can use selective detergent permeabilization, but we 
need a transmembrane torsinA construct with a cytosolic or nuclear epitope.  Thus, if the 
transmembrane construct is localized to the ER/ONM, the epitope will be accessible in 
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the cytosol, and revealed after plasma membrane permeabilization.  However, if the 
transmembrane construct is INM localized, the epitope will face the nucleoplasm, and 
will only be accessible after complete membrane permeabilization.  The requirement for 
a transmembrane construct presents an issue, because torsinA is normally a luminal, 
peripherally associated membrane protein.  We modified torsinA with a c-myc epitope 
and an alpha helical transmembrane domain (CHL), rather than the monotopic membrane 
association domain, so that NE concentrated ΔE torsinA would have a c-myc epitope in 
the cytosol (ONM localization) or nucleoplasm (INM localization).   
We also want to address how ΔE torsinA concentrates in the NE.  LULL1 retargets WT 
torsinA to the NE, but it is unclear whether LULL1 has an effect on the NE concentration 
of ΔE torsinA (14).  We used siRNA to knock down LULL1 levels in a mouse neuronal 
line (CAD) where ΔE torsinA is normally concentrated in the NE.  Our work will answer 
whether both WT and ΔE torsinA are affected by LULL1, or if ΔE torsinA is directed to 
the NE by a distinct mechanism.   
Next, we focused on why ΔE torsinA concentrates in the NE.  Strangely, ΔE torsinA is 
ER localized in certain in vitro cell lines, similar to the localization of WT torsinA 
(Figure 2.1).  Variability in ΔE torsinA localization seems to relate to an intrinsic 
difference between cell types (14).  We hypothesized that levels of torsinA interacting 
partners might modulate NE concentration of torsinA.  TorsinA interacting partners 
LULL1 and NE resident LAP1 are the only two torsinA partners verified by multiple 
studies; recent evidence has also associated torsinA with the NE resident LINC complex 
component SUN1 (8, 13, 22).  Previously, work in the Goodchild Lab has focused only 
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on in vitro cell lines where ΔE torsinA is normally NE concentrated; our work identified 
that siRNA depletion of LULL1 and SUN1 levels reduces NE concentration of ΔE 
torsinA, but siRNA depletion of LAP1 levels does not affect ΔE torsinA NE 
concentration (13).  Thus, our previous work established that both SUN1 and LULL1 are 
necessary for ΔE torsinA NE concentration, but it is unclear whether they are sufficient to 
promote the NE localization of ΔE torsinA.  For our current study, we developed a cell-
based overexpression assay in a cell line (CHO) where ΔE torsinA is normally localized 
to the ER.  In this system, we can overexpress torsinA interacting partners to modulate 
ΔE torsinA relocalization to the NE. We hypothesized that ΔE torsinA binds to an INM-
localized partner, and overexpression of the INM partner would increase ΔE torsinA INM 
concentration.   
LULL mediated relocalization of torsinA presents an intriguing research question. 
Previous research has shown that truncation of the torsinA monotopic membrane domain 
abrogates LULL1 mediated targeting, and the truncated torsinA construct remains ER 
localized (32).  Thus, it is attractive to hypothesize that the specific torsinA membrane 
domain may be required for the LULL1 mechanism.  We tested whether a modified 
transmembrane torsinA construct, lacking the monotopic membrane association domain, 
could be effectively targeted to the NE.   
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Methods 
Plasmid generation and siRNA 
Constructs were generated in pcDNA 3.1 vector.  A sequence encoding a single c-myc 
epitope was ligated into the HindIII site to generate a 1-myc full length human LULL1 
construct, followed by ligation of a sequence encoding a tandem c-myc epitope into the 
NheI site to generate 3-myc LULL1 constructs, which were used for all quantification 
studies (called “myc” constructs).  1myc-CHL-ΔE torsinA was generated using a plasmid 
from Dr. Howard Worman (Columbia Univerisity), and a tandem c-myc epitope was 
ligated into a HindIII site to generate 3myc-CHL-ΔE torsinA.  LULL1 knockdown was 
performed using siRNA oligonucleotides targeted at basepair 894 in NM_172843: (GGA 
CCU AUG GUU CCG UGU U; AAC ACG GAA CCA UAG GUC C) and is matched 
with control duplex (GGA UAU UGG CCU UGC CGU U; AAC GGC AAG GCC AAU 
AUC C).   
Cell culture and transfections 
CHO cells were obtained from the ATCC and cultured using recommended conditions.  
CAD cells were a kind gift from Dr. Bill Dauer (Columbia University) and cultured using 
recommended conditions.  Cells destined for immunofluorescent labeling were cultured 
on collagen (Sigma) coated coverslips (Carolina Biological Supply); CAD cells were 
cultured on poly-D-lysine coated coverslips.  Plasmid transfections were performed using 
Lipofectamine LTX and Lipofectamine Plus reagent (Invitrogen) according to the 
manufacturer’s instructions.  Transfected cells were fixed at 24 h post-transfection by 20 
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min incubation with 4% formaldehyde, followed by washing with 1 X PBS.  SiRNA 
transfections were performed using RNAiMAX reagent (Invitrogen) according to the 
manufacturer’s instructions.  Treated cells were fixed at 48 h post-transfection as 
described above.   
Immunolabeling 
Cells cultured on collagen-coated cover-glasses were transferred to a ParaFilm support 
within a humidified chamber, incubated for 1 h at room temperature in normal donkey 
serum (NDS; Jackson Immunoresearch) block solution (1 x PBS, 0.25% Triton X-100, 
10% NDS).  Cells were then incubated overnight at 4°C in NDS-blocking solution 
containing primary antibodies.  Polyclonal anti-GFP used to detect GFP-torsinA has been 
previously described(13).  Monoclonal anti-myc antibodies were from mouse anti-myc 
clone 9E10 (ATCC).  The following day, samples were washed six times with 1 x PBS, 
incubated for 1 h with secondary antibodies diluted in NDS-blocking solution, washed 
and prepared for fluorescent microscopy by inverting coverslips into ‘Vectashield with 
DAPI’ or ‘Vectashield without DAPI’ (Vector Laboratories) on a microscope slide.  
Fluorescent secondary antibodies used to visualize labeled coverslips were from Jackson 
Immunoresearch.  Labeled samples were examined using a Nikon Eclipse Ti and imaged 
with Nikon Digital Sight DS-QiMc camera and NIS-elements BR3.0.   
For selective permeabilization with digitonin, cells were fixed with 4% formaldehyde as 
described above, followed by permeabilization with 0.004% digitonin in PBS for 14 min 
at 4°C.  Coverslips used for complete permeabilization were next incubated with 0.25% 
Triton X100 for 5 min.  All subsequent washing, block, and labeling steps were 
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performed in 1XPBS with no detergent.  Permeabilization was monitored using INM-
localized laminB labeling, which is only accessible to antibody labeling after complete 
membrane permeabilization.   
Quantification and statistical analysis 
Immunofluorescently labeled coverslip cultured cells were used for statistical 
quantification.  Quantification of the relative amounts of NE and ER localized GFP-
torsinA fluorescence was performed on transfected cells co-labeled with antibodies 
against GFP and the myc epitope tag present on LULL1 constructs.  All quantification 
was conducted blind to the LULL1 construct.  Labeled samples were examined using a 
Nikon Eclipse Ti inverted microscope with Nikon Digital Sight DS-QiMc camera and 
NIS-elements BR3.0 software.  Images of GFP-positive cells were captured so that the 
focal plane visualized the NE.  For GFP exposure images, exposures were 150 
milliseconds or greater and images with saturated signal were excluded to avoid analysis 
of highly expressing cells.  To account for possible expression differences between 
different LULL1 constructs, myc exposure times were exactly 150 milliseconds for each 
image.  The highest NE localized pixel intensity was used as a measure of NE-localized 
fluorescence.  ER localized GFP signal was calculated as an average of pixel intensities 
between 0.5 micrometer and 1micrometer distance from the NE.  We measured a 
background fluorescence measurement from a region in the field that lacked cells and 
subtracted this value from NE and ER signal measurements.  GraphPad Prism was used 
to analyze the ratios of NE/ER localized fluorescence collected from each cell, including 
calculation of mean, s.e.m, One-Way ANOVA, T-Test, and post-hoc analysis.  All graphs 
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show the mean and standard error (s.e.m.) of these values.  Quantification methods were 
modified from Jungwirth et al(33).  For selective permeabilization studies, the percentage 
of cells containing NE-concentrated transmembrane ΔE torsinA (myc-CHL-torsinA) was 
assessed by blinded quantification of c-myc signal and localization in 100 cells that were 
permeabilized with digitonin or Triton X100 (as described earlier) that were also 
immunoreactive for GFP (anti-GFP labeling of GFP-LULL1). Statistical analysis was 
performed using GraphPad Prism.    
Results 
ΔE torsinA is present in the INM subdomain of the NE 
We tested whether NE-localized ΔE torsinA is present at the INM or at the ONM using 
epi-fluorescence microscopy of myc-fusion proteins, visualized with anti-myc antibody 
after either selective plasma membrane permeabilization using digitonin or complete 
membrane permeabilization using Triton X100.  We utilized the transmembrane ΔE-
torsinA construct to uncover whether LULL1-dependent NE-concentration reflects an 
INM or ONM ΔE-torsinA localization (Figure 2.2A).  Cells cotransfected with myc-CHL 
ΔE-torsinA and GFP-LULL1 were permeabilized with either digitonin (only the cytosolic 
c-myc exposed) or Triton X100 (exposes cytosolic and nuclear c-myc-tag) (Figure 2.2B).  
This analysis found that TritonX-100 permeabilization was required to detect NE-
localized c-myc tagged transmembrane ΔE-torsinA, and very few digitonin permeabilized 
cells displayed NE-concentrated myc signal (Figure 2.2B).  We also compared the 
percentage of transfected cells (with GFP labeling of GFP-LULL1) that displayed NE-
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concentrated c-myc signal after digitonin or TritonX-100 treatment (Figure 2.2C).  This 
revealed a significant difference (p<0.002, Student’s Two-Tailed T-test), verifying the 
qualitative assessment and strongly indicating that LULL1-dependent NE localization of 
ΔE-torsinA reflects that ΔE-torsinA concentrates on the INM. 
LULL1 is required for ΔE torsinA NE accumulation  
We next asked whether LULL1 is required for NE concentration of ΔE torsinA.  We co-
transfected siRNA targeting LULL1 and GFP-ΔE torsinA in CAD cells, a mouse 
neuronal cell line where ΔE torsinA is NE concentrated.  To semi-quantitatively examine 
GFP-ΔE torsinA localization in situ, we measured the relative amount of NE and ER-
localized GFP signal in individual cells.  After treatment with control siRNA, LULL1 
remains strongly concentrated in the NE, with a relative NE/ER localized GFP-ΔE 
torsinA fluorescence with a mean ± s.e.m. of 1.811 ± 0.08 (n=25) (Figure 2.3A, top 
panel).  After treatment with LULL1 siRNA, GFP-ΔE torsinA appears equally distributed 
between the NE and ER system, and results in a NE/ER localized GFP signal with a 
mean ± s.e.m. of 1.032 ± 0.02 (n=25) (Figure 2.3A, bottom panel).  Analysis revealed a 
significant difference between GFP-ΔE torsinA localization in control and LULL1 
siRNA treated cells (p<0.0001, Student’s Two-Tailed T-test) (Figure 2.3B).  Our results 
confirm that LULL1 is not only important for WT torsinA NE accumulation, but is also 
required for ΔE torsinA INM localization. 
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LULL1 overexpression targets ΔE torsinA to the NE, but NE-localized 
binding partners have no effect   
We developed a cell-based overexpression assay to test the ability of torsinA interacting 
partners to relocalize GFP-ΔE torsinA to the NE in a cell line (CHO) where it is normally 
ER localized.  Our assay studies whether overexpression of torsinA interacting partners 
can ‘normalize’ GFP-ΔE torsinA to the NE, the site of ΔE torsinA mislocalization.  The 
typical subcellular localization of NE-residents LAP1 and SUN1, and ER-localized 
LULL1, is depicted in Figure 2.4A.  To semi-quantitatively examine GFP-ΔE torsinA 
localization in situ, we measured the relative amount of NE and ER-localized GFP signal 
in individual cells.  We used the ER-localized membrane protein, myc-FLAG-CHL as a 
control, because it does not interact with torsinA.  Co-expression with myc-FLAG-CHL 
does not target ΔE torsinA to the NE; GFP-ΔE torsinA signal remained equally 
distributed between the NE and ER system.  myc-FLAG-CHL co-expression with GFP-
ΔE torsinA results in a relative NE/ER localized GFP-ΔE torsinA fluorescence with a 
mean ± s.e.m. of 1.026 ± 0.02 (n=20) (Figure 2.4B, top panel; quantification in Figure 
2.4C).  As expected, overexpression of myc-LAP1 and myc-SUN1 resulted in NE 
accumulation of the constructs, but overexpressed protein also accumulated in the bulk 
ER, as depicted in Figure 2.4B.  Cells co-expressing NE residents LAP1 or SUN1 did not 
retarget ΔE torsinA to the NE, resulting in a similar distribution of GFP-ΔE torsinA 
between the NE and ER (Figure 2.4 B).  Co-expression of GFP-ΔE torsinA with LAP1 or 
SUN1 resulted in a relative NE/ER localized GFP signal with a mean ± s.e.m of 0.992 ± 
0.02 (n= 20) and 0.974 ± 0.04 (n= 20), respectively (Figure 2.4B, middle panels; 
quantification in Figure 2.4C).  When GFP-ΔE torsinA is co-expressed with ER-resident 
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LULL1, ΔE torsinA is significantly relocalized (p<0.0001, 1-way ANOVA with 
Bonferroni post-hoc analysis) to the NE, resulting in a relative NE/ER localized GFP-ΔE 
torsinA fluorescence with a mean ± s.e.m of 1.655 ± 0.07 (n= 20) (See Figure 2.4A, 
bottom panel; quantification in Figure 2.4B).  Our results suggest that increasing 
expression of LULL1, but not NE-residents LAP1 and SUN1, promotes ΔE torsinA to 
relocalize to the NE in a cell line where it is normally distributed in the bulk ER system.  
The torsinA monotopic membrane association domain is not required for 
LULL1 retargeting 
We utilized our transmembrane ΔE torsinA construct (described earlier in this Chapter) 
to test whether the torsinA monotopic membrane association domain is specifically 
required for LULL1 to affect the NE localization torsinA (Figure 2.5A).  Cells were co-
transfected with myc-CHL-ΔE torsinA and YFP-ER or GFP-LULL and semi-
quantitatively assessed for the relative amount of NE and ER localized myc signal in 
individual cells (Figure 2.5B, compare upper and lower panels).  Co-expression with 
YFP-ER resulted equal distribution of myc-CHL-ΔE torsinA between the NE and ER 
system, and resulted in a relative NE/ER localized myc-CHL-torsinA fluorescence with a 
mean ± s.e.m. of 0.878 ± 0.08 (n=20).  However, co-expression with GFP-LULL1 
significantly retargeted (p<0.0001, Student’s Two-Tailed T-Test) myc-CHL-ΔE torsinA 
to the NE, resulting in a relative NE/ER localized myc-CHL-torsinA fluorescence with a 
mean ± s.e.m. of 2.422 ± 0.15 (n=20) (Figure 2.5C).  Our analysis shows that myc-CHL-
ΔE torsinA NE localization can be promoted by co-expression with LULL1.  These 
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results strongly indicate that the torsinA monotopic membrane association domain is not 
required for LULL1 to retarget ΔE torsinA to the INM.   
 
Discussion 
ΔE torsinA is present in the INM subdomain of the NE 
Our data has confirmed that ΔE torsinA accumulation occurs at the INM, which provides 
insight into the way the ΔE deletion might affect normal protein function (Figure 2.2B-
C).  Recent studies have associated ΔE torsinA with both INM and ONM localized 
binding partners, and this has led different groups to propose opposing models for ΔE 
torsinA dysfunction that are difficult to reconcile (5, 13, 14, 30, 31).  In particular, ΔE 
torsinA has been associated with both INM and ONM components of the NE-spanning 
LINC complex (13, 14, 30).  SiRNA mediated reduction of INM-localized SUN1 
removes ΔE torsinA NE concentration (13).  Interaction studies suggest that ΔE torsinA 
binds ONM resident nesprin proteins (30), yet siRNA mediated knockdown of nesprin 
levels has no effect on ΔE torsinA NE accumulation (13).  INM localization of ΔE 
torsinA argues against interaction of ΔE torsinA with the ONM-localized nesprin 
component of the LINC complex, as previously reported (30).  Moreover, INM 
localization of ΔE torsinA supports recent evidence that the INM-localized SUN1 
component of the LINC complex is required for ΔE torsinA NE concentration (13).  
Because INM-localized LAP1 is required for WT torsinA function (29), it is attractive to 
hypothesize that both WT and ΔE torsinA are targeted to the INM, where WT torsinA 
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performs a function, and returns to the bulk ER system.  Furthermore, NE localization of 
both WT and ΔE torsinA is sensitive to siRNA reduction in SUN1 levels.  However, WT 
torsinA appears to be localized to the bulk ER system in in vitro cell lines, while ΔE 
torsinA is strongly concentrated in the NE in many in vitro cell lines.  Thus it seems 
likely that ΔE torsinA mislocalization could result from an abnormal association with a 
normal INM-localized binding partner(13), so that ΔE torsinA becomes ‘locked’ in the 
NE.   
Truncation of the torsinA membrane association domain abrogates LULL1-mediated 
retargeting activity (32).  It has been suggested that LULL1 may alter the conformation 
of the torsinA membrane domain so that torsinA can pass by the highly curved pore 
membrane to enter the INM (32).  However, a modified transmembrane ΔE torsinA 
construct, lacking the torsinA membrane association, is strongly targeted to the INM 
(Figure 2.5A-B).  Interestingly, the transmembrane ΔE construct is more strongly 
targeted to the INM compared to GFP-ΔE torsinA, which contains the monotopic 
membrane association domain (compare Figure 2.4C and 2.5C).  However, both 
constructs remain ER-localized unless LULL1 is overexpressed, which indicates that 
transmembrane ΔE torsinA retains the same targeting requirements as the full length 
protein.  The exact reason why transmembrane ΔE torsinA is more strongly retargeted to 
the NE is unclear, but one explanation may be that the GFP tag on LULL1 promotes 
homodimerization (mulimerization of LULL1 is explored in Chapter 4).  Our data 
strongly indicates that the specific torsinA monotopic membrane association domain is 
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not required for LULL1 activity, as previously proposed (32), yet torsinA must be 
membrane associated for LULL1-mediated retargeting.   
ER-resident LULL1 is required for NE targeting of ΔE torsinA, but NE-
localized binding partners have no effect in an overexpression paradigm 
The diffusion-retention model is considered to be the classic mode of NE targeting for 
membrane proteins.  TorsinA has several known INM-localized interacting partners 
(Figure 2.4A) (14, 22).  Our previous work has focused on siRNA knockdown of 
interacting partners to redistribute torsinA from the NE to the ER.  Previously, we have 
identified that siRNA knockdown of INM-resident LAP1 expression reduces NE-
localized E171Q torsinA NE accumulation, but does not affect ΔE torsinA (13, 33).  
Furthermore, siRNA mediated reduction of INM-localized SUN1 reduces both WT and 
ΔE torsinA NE concentration (13).   
We developed a cell-based overexpression paradigm in a cell line (CHO) where ΔE 
torsinA is normally localized to the ER.  We hypothesized that ΔE torsinA binds to an 
INM-localized partner, and overexpression of the INM partner would generate more INM 
binding sites for ΔE torsinA, and thus would lead to redistribution of ΔE torsinA to the 
INM.  Increasing the levels of an NE-partner translated as increasing the amount of 
torsinA accumulated at the NE makes sense with the classic diffusion retention model.  
However, we find that overexpression of LAP1 and SUN1 do not redistribute ΔE torsinA 
to the INM; only LULL1 overexpression causes INM accumulation of ΔE torsinA 
(Figure 2.4B).  Because of our previous siRNA results, we hypothesize that ΔE torsinA 
interacts with an INM-localized partner, likely to be LINC complex component SUN1 
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(13).  However, it seems that ΔE torsinA must be ‘modified’ by LULL1 to access the 
INM.  Thus, regardless of INM-partner overexpression, ΔE torsinA cannot reach INM 
binding partners without LULL1 activity.  This suggests a complex mechanism for 
torsinA INM targeting and argues against the diffusion-retention model as the sole 
explanation for torsinA NE accumulation.  However, it is unclear whether LULL1 
promotes ΔE torsinA NE concentration by allowing torsinA to access the INM 
(“movement”) versus modification of torsinA so that it can interact with another INM 
localized interacting partner (“binding”), most likely the LINC complex component 
SUN1.  To differentiate between these hypotheses, we can simultaneously use siRNA to 
knockdown SUN1 levels while overexpressing LULL1 and GFP-ΔE torsinA in CHO 
cells, where ΔE torsinA is normally localized to the bulk ER system.  Thus, if LULL1 
allows ΔE torsinA to access the INM, but does not promote SUN1 binding, ΔE torsinA 
will concentrate in the NE, despite reduction of SUN1 levels.  However, we hypothesize 
that LULL1 modifies ΔE torsinA so that it binds SUN1 and is retained at the INM 
through this interaction.  We suggest that reduction of SUN1 levels will abrogate 
LULL1-mediated relocalization of ΔE torsinA.   
An ER-localized mechanism for the targeting of another ER localized protein to the NE 
has never been described.  However, very little is known about LULL1 or the mechanism 
of its activity, and there are many possible models that could explain how LULL1 
retargets ΔE torsinA from the bulk ER system to the INM.  LULL1 appears to remain 
localized to the main ER system even when ΔE torsinA is targeted to the INM.  However, 
is possible that a small subset of LULL1 is present at the INM, and functions as an INM 
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binding partner to anchor ΔE torsinA in the INM.  Furthermore, LULL1 may physically 
shuttle torsinA between the bulk ER and the INM, or perhaps LULL1 function takes 
place solely in the bulk ER system.  For example, ER-localized LULL1 could alter the 
structure of ER-localized torsinA to promote interaction with an INM-localized binding 
partner.  Each model for possible LULL1 mechanisms has a requirement for a specific 
LULL1 subcellular localization; for example, we can eliminate the possibility that 
LULL1 acts as an INM anchor for torsinA if a subset of LULL1 does not relocalize to the 
INM.  Differentiating between ER-localized function and INM function of LULL1 is the 
first step to narrow down potential mechanisms for LULL1 activity.  In Chapter 3, we 
investigate relative importance of the domains of LULL1 and address whether LULL1 
performs a function in the main ER system, or partially relocalizes to the INM with 
torsinA.   
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Figure 2.1: ΔE torsinA is variably localized to the ER or NE in in vitro cell lines 
Images show CAD cells (left panel) or CHO cells (right panel) transfected with GFP-ΔE 
torsinA.  Scale bar represents 10μm.  
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Figure 2.2: GFP-LULL1 overexpression targets transmembrane ΔE torsinA to the 
INM 
A. Schematic shows full length torsinA (top) and transmembrane myc-CHL torsinA 
(bottom).  The black box labeled “Hypb” represents the torsinA monotopic membrane 
association domain.  The red box represents the c-myc epitope tag used for 
immunofluorescence imaging.  B.	  Images	  show	  anti-­‐myc	  labeling	  (left	  panel),	  anti	  GFP	  labeling	  (middle	  panel),	  and	  merged	  images	  (right	  panel)	  of	  CHO	  cells	  co-­‐transfected	  with	  myc-­‐CHL-­‐ΔE	  torsinA	  and	  GFP-­‐LULL1	  after	  either	  selective	  permeabilization	  using	  digitonin	  (top)	  or	  complete	  permeabilization	  using	  Triton	  X100	  (bottom).	  	  C.	  Bars	  represent	  the	  percentage	  of	  cells	  with	  NE	  localized	  signal	  after	  digitonin	  or	  Triton	  X100	  permeabilization.	  	  Cells	  were	  randomly	  selected	  for	  analysis,	  and	  bars	  show	  the	  mean	  ±	  s.e.m.	  from	  two	  separate	  experiments.	  	  Triton	  X100	  permeabilization	  results	  in	  a	  significantly	  	  increased	  number	  of	  cells	  with	  NE	  labeling	  (signified	  by	  **;	  p<0.002;	  Student’s	  Two-­‐tailed	  T-­‐Test)	  compared	  to	  selective	  permeabilization	  using	  digitonin.	  	  Abbreviations:	  Triton	  X100	  =	  TX100.	  
Scale bar represents 10μm.  
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Figure 2.3: LULL1 is required for ΔE torsinA accumulation at the NE 
A. Images show anti-GFP labeling of CAD neuronal cells co-transfected with GFP ΔE 
torsinA and control (top) or LULL1 siRNA duplexes (bottom).  B. Bars show the mean ± 
s.e.m. of the ratio of NE-localized / ER-localized GFP-ΔE torsinA after co-expression 
with control or LULL1 siRNA.  Cells were selected at random and ratios were generated 
for cells with NE-localized and ER-localized ΔE torsinA. LULL1 siRNA significantly 
reduces the ratio between NE and ER localized ΔE torsinA signal (represented by ****).  
(N=25 cells per condition;  p<0.0001).  Student’s Two tailed T-Test.  Scale bar represents 
10μm.  
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Figure 2.4: LULL1 overexpression targets GFP-∆E torsinA to the NE, but INM-
localized binding partners have no effect 
A.  Schematic showing the relative localization of NE-residents LAP1 and SUN1 and 
ER-resident LULL1.  B. Images show anti-GFP labeling (left panel), anti-myc labeling 
(middle panel) and merged images (right panel) of CHO cells co-transfected with GFP-
ΔE torsinA and a myc tagged interacting partner.  C. Bars show the mean ± s.e.m. of the 
ratio of NE localized immunoreactivity/ ER-localized immunoreactivity for GFP-ΔE 
torsinA when co-expressed with four different proteins.  FLAG-CHL is a control 
membrane protein that does not interact with torsinA.  **** indicate cells where ER-
localized ΔE torsinA displays a significantly higher NE/ER ratio (more NE labeling) after 
co-expression with myc-LULL1 compared to cells where ΔE torsinA is localized to the 
ER (N = 20 cells per condition; p<0.0001) after co-expression with myc-LAP1, myc-
SUN1 or FLAG-CHL.  One-Way ANOVA with Bonferroni Post Hoc analysis.  Scale bar 
represents 10µm.  
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Figure 2.5: The torsinA monotopic membrane association domain is not required 
for LULL1 retargeting 
A. Schematic shows full length torsinA (top) and myc-CHL torsinA (bottom). The black 
box labeled “Hypb” represents the torsinA monotopic membrane association domain.  
The red box represents the c-myc epitope tag used for immunofluorescence imaging.  B. 
Images show anti-myc labeling (left panel), anti-GFP labeling (middle panel) and merged 
images (right panel) of CHO cells co-transfected with myc-CHL ΔE torsinA and GFP-
LULL1.  C. Bars	  show	  the	  mean	  ±	  s.e.m.	  of	  the	  ratio	  of	  NE	  localized	  immunoreactivity/	  ER-­‐localized	  immunoreactivity	  for	  myc-­‐CHL-­‐ΔE	  torsinA	  when	  co-­‐expressed	  with	  control	  protein	  YFP-­‐ER	  or	  GFP	  LULL1.	  	  YFP-­‐ER	  is	  a	  control	  protein	  that	  is	  ER	  localized	  and	  does	  not	  interact	  with	  torsinA.	  	  Cells were selected at 
random for analysis and ratios were generated for cells with NE-localized and ER-
localized myc-LULL1.  ****	  indicates	  cells	  where	  ER-­‐localized	  ΔE	  torsinA	  displays	  a	  significantly	  higher	  NE/ER	  ratio	  (more	  NE	  labeling)	  after	  co-­‐expression	  with	  GFP-­‐LULL1	  than	  cells	  where	  ΔE	  torsinA	  is	  localized	  to	  the	  ER	  after	  co-­‐expression	  with	  YFP-­‐ER	  (N	  =	  20	  cells	  per	  condition;	  p<0.0001,	  Students	  Two-­‐Tailed	  T-­‐Test)	  Scale	  bar	  represents	  10μm.	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CHAPTER 3 : 
MULTIPLE DOMAINS OF ER-LOCALIZED LULL1 ARE REQUIRED 
FOR ACTIVITY, BUT HETEROLOGOUS PROTEIN FRAGMENTS 
CAN COMPLEMENT FOR LOSS OF THE CYTOSOLIC DOMAIN 
Introduction 
Our results in Chapter 2 established that LULL1 has a key role in ΔE torsinA NE 
localization, but very little is known about the protein.  Furthermore, the mechanism of 
LULL1 function is unclear.  To date, an ER-localized mechanism of a protein, causing 
another ER protein to accumulate in the NE, has never been identified.  Several different 
hypotheses could explain LULL1 activity.  For example, LULL1 may physically 
transport torsinA from the main ER system to the INM, or LULL1 may act as an INM 
anchor to ‘lock’ ΔE torsinA in the INM.  However, because these models require a 
specific subcellular localization of LULL1, we can eliminate potential models by 
identifying the site of LULL1 activity.  Although LULL1 appears to remain diffusely 
localized in the main ER system when ΔE torsinA is concentrated in the NE, it is possible 
that LULL1 function requires a subset of LULL1 to be INM localized.  We tested 
whether LULL1 is active when it is restricted to the main ER system, and cannot access 
the INM.  The cytosolic domain size restriction imposed on proteins entering the INM 
has been exploited in previous NE-targeting studies (18, 34, 35).  The size of full length 
LULL1 should allow it to access the ER/ONM as well as the INM, so we generated a 
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modified LULL1 construct by attaching a large ER-restriction domain to the cytosolic 
domain of LULL1.  ER-restriction domains have been used in previous studies to ‘trap’ 
INM-directed proteins in the ER/ONM (18, 34, 35).  In addition, we used a different 
methodology to test whether a small subset of ‘active’ LULL1 is present at the INM.  We 
used selective detergent permeabilization to test whether a subset of LULL1 is present at 
the INM (similar to experiments described in Chapter 2).  LULL1 is a transmembrane 
protein; therefore, we added a c-myc epitope tag, so that the c-myc tag would face the 
cytosol (ER/ONM localization) or face the nucleoplasm (INM localization).  
Furthermore, we also tested whether LULL1 is active in the INM.  We modified LULL1 
so it would be localized to the INM by adding the nucleoplasmic domain of LAP1 
(LAP1nuc), which interacts with lamin proteins in the INM.   
We next focused on broad analysis of the domains of LULL1.  LULL1 is a 70kDa single 
transmembrane ER resident protein with no identified functional domains, and no 
identified binding partners other than torsinA, which interacts with the luminal domain of 
LULL1 (4).  Furthermore, the cytosolic domain of LULL1 lacks a stably folded structure 
according to prediction software (PredictProtein; http://www.predictprotein.org/).  
Because LULL1 is a transmembrane protein, it could potentially deliver cytoplasmic 
signals to torsinA (36).  We broadly analyzed the relative importance of the LULL1 
luminal torsinA-interacting domain, and the putatively unstructured cytosolic domain.   
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Multiple lines of evidence have suggested that WT torsinA is important at the NE (28, 
29), and WT torsinA accumulates at the NE after LULL1 overexpression(14).  Thus, 
LULL1 is likely to be important to the normal biochemical mechanism of torsinA.  We 
hypothesized that LULL1 might dynamically regulate the localization of torsinA in vivo.  
We analyzed predicted post-translational modifications, and found that the LULL1 
cytosolic domain has a large number of “highly predicted” phosphorylation sites 
(NetPhos; http://www.cbs.dtu.dk/services/NetPhos).  Differential phosphorylation of 
effector proteins is a well-established regulatory element of many cellular pathways (19), 
so LULL1 activity could be controlled by differential phosphorylation.  We performed 
site directed mutagenesis to eliminate potential phosphorylations, in order to broadly test 
whether differential phosphorylation could affect LULL1 targeting function.   
At the same time as our ER-restriction analysis, we added heterologous domains to the 
luminal torsinA-interacting domain of LULL1, which lacks the cytosolic domain.  We 
tested whether chimeric luminal LULL1 constructs retained the ability to retarget ΔE 
torsinA to the NE.  These analyses have provided insight into possible functions of the 
LULL1 cytosolic domain.   
Methods 
Plasmid generation 
All constructs were cloned into pcDNA 3.1 (Invitrogen).  PCR amplification used 
Platinum Taq high fidelity PCR (Invitrogen) and site-directed mutagenesis used 
Quikchange (Stratagene), both according to the manufacturer’s instructions.  We fully 
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sequenced PCR-generated constructs to ensure fidelity of amplification.  The luminal 
LULL1 construct (myc-208 LULL1) was generated using the modified Nhe-Nhe208 
LULL1, a construct in which the cytosolic domain is flanked by NheI restriction sites. 
The cytosolic domain was removed by NheI digestion and re-ligation.  A tandem c-myc 
epitope sequence was ligated into the NheI restriction site, as described in Chapter 2. The 
cytosolic domain construct myc-1-208 LULL1 was available in the lab.  The G. gallus 
CMPK protein fragment was amplified from plasmid p3PK (Dr. Howard Worman, 
Columbia University) using AAGCTAGCCTGCACGCTGCCATGGCAGAC and 
ACTCTAGAGGGCTGCTTGCAGCACACGGG primers, followed by ligation into the 
myc-LULL or myc-208 LULL sequence using the NheI restriction site.  The human 
LAP1 nucleoplasmic domain was amplified using 
CCCGCTAGCATGAAGACGCGAAGGACTACC and 
CCCGCTAGCATGAAGACGCGAAAGGACTACC primers, followed by ligation into 
the myc-LULL or myc-208 LULL sequence using the NheI restriction site.  The S. 
japonicum GST sequence was amplified from pDEST15 plasmid using 
CCCGCTAGCTCCCCTATACTAGGTTATTGG and 
GGGTCTAGATGTTTGATTCGACCATGGACG primers and ligated into the myc-208 
LULL1 sequence using the NheI restriction site.  The A. thaliana MYA1 protein 
fragment was amplified from pET30a MYA1 (Dr. Andreas Nebenfuehr, University of 
Tennessee) using CCCGCTAGCGATAGCCCCCAGAAATCGCTTAATC and 
GGGTCTAGAATCTGACCTTTCCAACAAGAAC and ligated into the myc-LULL1 
sequence using the NheI restriction site.  GCN4-MYA1 was amplified from pET30a 
GCN4-MYA1 (Dr. Andreas Nebenfuehr, University of Tennessee) using 
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CCCGCTAGAATGAAACAACTTGAAGACAAG and 
GGGTCTAGAATCTGACCTTTCCAACAAGAAC followed by ligation into the myc-
208 LULL1 sequence using the NheI restriction site.  PCR mutagenesis was performed 
on myc-LULL1 to mutate codons 66, 70 and 72 to alanine (T66A/S70A/S72A); or to 
mutate codons 120 and 122 to alanine (S120A/S122A); or to mutate codons 163 and 167 
to alanine (S163A/S167A).   
Cell culture, transfections, immunolabeling, and quantification 
Cell culture, transfections, immunolabeling and quantifications were performed 
essentially as described in Chapter 2.  HEK293 cells (used for protein characterization 
studies, described below) were a gift from Dr. Madhu Dhar.   
Protein characterization 
Myc-LULL1 construct levels and glycosylation states were assessed by extracting 
proteins from transfected HEK293 cells by homogenization in extraction buffer (1% 
SDS, 50mM Tris HCl pH 7.4, 150mM NaCl, 1mM PMSF (Sigma), 1 x Protease Inhibitor 
Cocktail (Sigma).  Proteins were solubilized by mechanical disruption followed by 20 
min incubation with rotation, and then insoluble material was removed by centrifugation 
for 10 min at 20000g.  Protein concentrations were determined using the BCA protein 
assay (Pierce).  The glycosylation state of LULL proteins present in 50ug of 1% SDS 
extracted transfected CHO cell lysates were assessed using EndoH (New England 
Biolabs) according to the manufacturer’s instructions, followed by SDS-PAGE and anti-
myc Western blotting.   
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Western blotting 
Western blotting of nitrocellulose membranes or PVDF membranes (Biorad) used 
standard blocking, primary antibody and washing steps.  Mouse monoclonal anti-myc 
(derived from mouse anti-myc 9E10 clone (ATCC) as described in Chapter 2) was used 
as a primary antibody to detect myc-tagged LULL1 constructs.  Primary antibodies were 
detected using peroxidase conjugated Immunopure secondary antibodies (Pierce) or light 
chain specific anti-rabbit (Jackson Immunoresearch).  Peroxidase activity was assessed 
using Supersignal West Dura reagent (Pierce) and visualized by exposure to Hyblot film 
(Denville Scientific).  
Results 
ER-localized LULL1 activity is required for ΔE torsinA accumulation 
We tested whether a subset of LULL1 is present at the INM using epi-fluorescence 
microscopy of c-myc-fusion proteins, visualized with anti-myc antibody after either 
selective plasma membrane permeabilization using digitonin or complete membrane 
permeabilization using Triton X100.  We added a c-myc epitope tag to LULL1, which is 
a transmembrane protein; thus, the myc tag would be accessible to the cytosol if the 
construct is ER/ONM localized, or present in the nucleoplasm if the construct is INM 
localized.  Cells transfected with myc-LULL1 were permeabilized with either digitonin 
(only the cytosolic c-myc exposed) or Triton X100 (exposes cytosolic and nuclear c-myc-
tag) (Figure 3.1A).  To semi-quantitatively assess myc-LULL1 localization in situ, we 
measured the relative amount of NE and ER-localized myc signal in individual cells.  
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This analysis found that TritonX-100 permeabilization does not reveal NE-localized myc 
signal, and digitonin permeabilized cells displayed similar levels of ER-localized myc 
signal (Figure 3.1A-B).  We also tested whether the localization of myc-LULL1 changes 
when GFP-ΔE torsinA is present in the INM. Cell co-transfected with myc-LULL1 and 
GFP-ΔE torsinA were permeabilized with either digitonin (only cytosolic c-myc 
exposed) or Triton X100 (exposes cytosolic or nuclear c-myc tag) (Figure 3.1C).  
Although digitonin selectively permeabilizes the plasma membrane, and does not 
permeabilize the ER membranes, the ONM is partially digitonin-sensitive, thus anti-GFP 
labeling of luminal GFP-ΔE torsinA is possible (Figure 3.1C, second panel).  Even when 
GFP-ΔE torsinA is present at the NE, Triton X100 permeabilization does not reveal 
additional INM-localized myc signal (Figure 3.1 C-D).  Our results verify the qualitative 
assessment that LULL1 does not relocalize to the NE with ΔE torsinA, and suggests that 
ΔE torsinA is targeted to the INM via an ER-localized LULL1 function.   
LULL1 remains functional when restricted to the ER 
We tested whether LULL1 is functional in the ER by adding ER-restriction domains to 
the LULL1 cytosolic domain (Figure 3.2A-B).  We modified full length LULL1 by 
adding a large domain from chicken muscle pyruvate kinase (CMPK) to the N-terminus 
of the LULL1 sequence (a kind gift from the Worman lab) (Figure 3.2B).  CMPK has 
been previously used to restrict INM-directed proteins to the ER/ONM (18, 34, 35).  We 
also generated a different ER-restricted LULL1 construct by adding the large globular 
MYA1 tail domain from A. thaliana (a kind gift from the Nebenfuehr lab), which Mr 
predicts to have the same ER restriction effect as CMPK (Figure 3.2B).  We used our 
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cell-based overexpression paradigm  (introduced in Chapter 2) to test whether our 
constructs could target GFP-ΔE torsinA from the ER to the NE.  Our assay addresses 
whether overexpression of LULL1 constructs can ‘normalize’ GFP-ΔE torsinA to the 
NE, the site of ΔE torsinA mislocalization.  To semi-quantitatively examine GFP-ΔE 
torsinA localization in situ, we measured the relative amount of NE and ER-localized 
GFP signal in individual cells.  Cells co-transfected with myc-CMPK LULL1 and GFP-
ΔE torsinA showed strong relocalization of ΔE torsinA to the NE, resulting in a relative 
NE/ER localized GFP-ΔE torsinA fluorescence with a mean ± s.e.m. of 1.620 ± 0.07 
(n=20)(Figure 3.2A, top panel; quantification shown in Figure 3.2C).  Cells co-
transfected with myc-MYA1-LULL1 and GFP-ΔE torsinA also showed a strong 
retargeting of ΔE torsinA to the NE, with relative NE/ER localized GFP-ΔE torsinA of 
1.711 ± 0.07 (n=20) (Figure 3.2A, middle panel; quantification shown in Figure 3.2C).  
Both myc-CMPK LULL1 and myc-MYA1 LULL1 significantly retargeted (p<0.0001, 1-
Way ANOVA with Bonferroni Post-Hoc analysis) GFP-ΔE torsinA to the NE compared 
to co-expression with control protein FLAG-CHL (Figure 3.2C).  Our results suggest that 
LULL1 can retarget ΔE torsinA to the INM even if it is restricted to the main ER system.   
INM localized LULL1 does not target ΔE torsinA to the INM 
We tested whether LULL1 is functional in the INM.  We added the lamin B receptor 
(LBR) nucleoplasmic domain, or the LAP1 nucleoplasmic (LAP1nuc) domain to full 
length LULL1.  Both of these domains interact with lamins that surround the nucleus and 
have been shown to target chimeric proteins to the INM (14, 17, 18).  However, the 
combined LULL1 cytosolic domain and INM targeting motifs of both LBR and LAP1nuc 
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was very large, and neither construct was efficiently targeted to the NE (not shown).  We 
continued our analysis using the LAP1 nucleoplasmic domain fused to the luminal 
domain of LULL1 (myc-LAP1nuc 208-LULL) (Figure 3.3A-B).  We used the cell-based 
overexpression paradigm (Chapter 2) to test whether INM-directed LULL1 can target ΔE 
torsinA to the INM.  To semi-quantitatively assess GFP-ΔE torsinA localization in situ, 
we measured the relative amount of NE and ER-localized GFP signal in individual cells.  
The myc-LAP1nuc-208 LULL1 construct is correctly targeted to the NE (Figure 3.3A, 
middle panel), yet we found that co-expression of this construct resulted in equal 
distribution of GFP-ΔE torsinA between the NE and the main ER system, with a relative 
NE/ER localized GFP-ΔE torsinA fluorescence intensity of 1.008 ± 0.03 (n = 20)(Figure 
3.3C).  This data implies that LULL1 is not functional in the INM, but additional research 
suggests that this experiment is not interpretable (described below).    
The torsinA interacting domain of LULL1 is required for retargeting of ΔE 
torsinA 
Next, we broadly analyzed the relative importance of LULL1 domains.  We tested 
whether the luminal torsinA interacting domain was required for LULL1 function.  We 
utilized the cell-based overexpression paradigm described in Chapter 2 to test the ability 
of LULL1 constructs to relocalize GFP-ΔE torsinA to the NE in a cell line (CHO) where 
it is normally ER localized.  For our analysis, we used a LULL1 construct that only 
expresses the cytosolic domain of LULL1, and lacks the luminal torsinA interaction 
domain  (Figure 3.4A-B).  The cytosolic fragment is not membrane associated and is 
present diffusely throughout the cytosol of the cell (Figure 3.4A, top middle panel).  To 
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semi-quantitatively examine GFP-ΔE torsinA localization in situ, we measured the 
relative amount of NE and ER-localized GFP signal in individual cells.  Cells co-
transfected with ER-localized control membrane protein FLAG-CHL showed equally 
distributed GFP ΔE signal in the NE and main ER, with a NE/ER GFP-ΔE fluorescence 
intensity with a mean ± s.e.m. of 1.045 ± 0.03 (n=20) (Figure 3.4A, bottom panel; 
quantification shown in Figure 3.4C).  Although co-expression with full length LULL 
shows a significant (p<0.0001, 1-Way ANOVA with Bonferroni Post-Hoc) increase in 
NE accumulation (Figure 3.4A middle panel), co-expression of the cytosolic fragment of 
LULL1 does not alter the localization of GFP-ΔE torsinA; signal remains distributed 
evenly between the NE and the main ER.  Cells co-transfected with the cytosolic LULL1 
fragment and GFP-ΔE torsinA showed a relative NE/ER GFP ΔE torsinA fluorescence 
intensity of 1.028 ± 0.05 (n = 20) Figure 3.4A, top panel; quantification shown in Figure 
3.4C. As expected, our data strongly indicates that the LULL1 torsinA interacting 
luminal domain is required to retarget ΔE torsinA to the NE.  
The cytosolic domain of LULL1 is required to target ΔE torsinA 
Next, we tested whether the LULL1 luminal domain is sufficient for LULL1 activity.  
We truncated the cytosolic domain to express only the C-terminal torsinA-interacting 
luminal domain (myc-208-LULL) (Figure 3.5A-B).  Luminal LULL1 localizes to the 
main ER system (Figure 3.5A, top middle panel). We utilized our cell-based 
overexpression paradigm (Chapter 2) to test whether this construct could target GFP-ΔE 
torsinA to the NE.  We semi-quantitatively examined GFP-ΔE torsinA localization in situ 
by measuring the relative amount of NE and ER-localized GFP signal in individual cells. 
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Coexpression of luminal LULL1 and GFP-ΔE torsinA did not redistribute GFP-ΔE 
torsinA to the NE; GFP-ΔE signal remains evenly distributed in the main ER system 
(Figure 3.5A).  Co-transfection with luminal LULL1 and GFP-ΔE torsinA results	  in	  a	  relative	  NE/ER	  GFP	  ΔE	  torsinA	  fluorescence	  intensity	  with	  a	  mean	  ±	  s.e.m	  of	  0.983	  ±	  0.02	  (n	  =	  20);	  compared	  to	  co-­‐expression	  with	  control	  FLAG-­‐CHL,	  which	  resulted	  in	  a	  mean	  ±	  s.e.m	  of	  0.968	  ±	  0.02	  (n	  =	  20)	  (Figure	  3.5C).	  This	  data	  suggests	  that	  the	  cytosolic	  domain	  of	  LULL1	  is	  required	  to	  target	  ΔE	  torsinA	  to	  the	  NE.	  	  	  
Mutation of putative phosphorylations of LULL1 has no effect on its ΔE 
retargeting ability 
We identified that the cytosolic domain was required for LULL1 function, so we further 
investigated its characteristics.  Prediction software revealed that the cytosolic domain of 
LULL1 has a large number of putative phosphorylation sites (NetPhos; 
http://cbs.dtu.dk/services/NetPhos) (not shown).  We developed an efficient mutagenesis 
strategy to target as many predicted serine and threonine phosphorylation sites as 
possible.  To narrow down possible important phosphorylation sites, we tested whether 
mouse LULL1 can retarget ΔE torsinA to the NE.  The cytosolic domain of mouse 
LULL1 is only 50% similar to the human protein, so our positive result highlighted 
specific serine and threonine residues of potential importance (Figure 3.6A, compare 
upper and lower panels).  We mutated specific seronine/threonine residues to alanine to 
eliminate phosphorylation possibility.  We generated constructs T66A/S70A/S72A; 
S120A/S122A; and S163A/S167A (Figure 3.6B-C).  The approximate location of 
residues mutated to alanine is shown in Figure 3.6C.  We qualitatively found that each of 
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our mutants strongly targeted ΔE torsinA (Figure 3.6B).  This suggests that 
phosphorylations are not required to promote ΔE torsinA NE accumulation, but it 
remains possible that phosphorylation modifications inhibit LULL1 activity.    
Multiple heterologous protein fragments can complement for loss of the 
required LULL1 cytosolic domain 
When we generated ER-restriction constructs using full length LULL1, we also generated 
a CMPK chimera with the luminal domain of LULL1, which lacks the LULL1 cytosolic 
domain (Figure 3.7A-B, top panel).  We tested whether this construct could retarget GFP-ΔE torsinA to the NE, expecting that it would be inactive.  However, cells co-transfected 
with myc-CMPK-208 LULL1 and GFP-ΔE torsinA showed a relative NE/ER localized 
GFP-ΔE torsinA fluorescence intensity of 1.489 ± 0.06 (n= 20); a surprising result, 
considering that our previous analysis had established that the cytosolic domain of 
LULL1 was required for function (Figure 3.7A, top panel; quantification shown in Figure 
3.7C).  Because of this strange result, we initially started to construct a different 50kDA 
ER-restriction domain to exclude myc-208 LULL1 from the INM.  However, we found 
that only one 25kDa GST domain was needed to fully complement for truncation of the 
cytosolic domain of LULL1 (Figure 3.7B), and co-expression of the construct resulted in 
a relative NE/ER localized GFP ΔE torsinA fluorescence intensity with a mean ± s.e.m. 
of 1.840 ± 0.11 (n=20) (Figure 3.7A, second panel; quantification shown in Figure 3.7C).  
A review of the literature suggests that GST and CMPK domains have only one obvious 
characteristic in common; they can both form higher-order structures (explored later in 
Chapter 4).  To further verify our results, we added another unrelated heterologous 
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domain to luminal LULL1, to generate GCN4-MYA1 208 LULL1, a chimeric fusion 
between the luminal domain of LULL1, and GCN4-MYA1, a coiled-coil dimerization 
domain (GCN4), and MYA1, an ER restriction domain used earlier in this Chapter 
(Figure 3.7A, third panel, Figure 3.7B).  Cells co-transfected with myc-GCN4-MYA1 
208 LULL1 and GFP-ΔE torsinA results in a relative NE/ER localized GFP-ΔE torsinA 
fluorescence intensity with a mean ± s.e.m of 1.621 ± 0.06 (quantification shown in 
Figure 3.7C).  Each chimeric 208-LULL1 construct was capable of significant 
relocalization (p<0.0001, 1-Way ANOVA with Bonferroni Post-Hoc analysis) of GFP-ΔE torsinA to the NE.  Our data implies that heterologous domains that are capable of 
dimerization can complement for the cytosolic domain of LULL1.   
LULL1 constructs are correctly oriented 
We verified that our chimeric constructs are correctly targeted to the ER and oriented so 
that the luminal domain of LULL1 can interact with torsinA.  We utilized our cell-based 
overexpression assay (Chapter 2) to test whether our constructs could displace NE-
localized GFP-E171Q torsinA.  As introduced in Chapter 1, E171Q torsinA is a predicted 
‘ATP-locked’ torsinA mutant that is localized to the NE in all cell lines (22).  ER-resident 
LULL1 has been shown to displace E171Q torsinA from the NE to the ER (22).  
Correctly-oriented constructs should displace GFP E171Q torsinA from the NE.  As a test 
analysis, we separately co-transfected myc-LULL1, myc-208 LULL1, myc-CMPK 
LULL1 and myc-CMPK 208 LULL1 with GFP E171Q torsinA (Figure 3.8A).  We find 
that each construct significantly displaces (p<0.0001, 1-Way ANOVA with Bonferroni 
Post-Hoc analysis) GFP-E171Q torsinA from the NE to the ER (Figure 3.8 A-B), 
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compared with co-expression of GFP-E171Q torsinA with FLAG-CHL, where GFP-
E71Q torsinA remains NE localized.  This data suggests that our constructs are correctly 
oriented so that the luminal, torsinA interacting domain is present in the ER.  We also 
performed glycosidase analysis on our constructs.  Endoglycosidase-H (EndoH) cleaves 
N-linked oligosaccarides that are added in the ER-lumen.  Because oligosaccarides 
become resistant to EndoH cleavage after enzymatic processing in the Golgi, EndoH 
sensitivity can be used to assess protein trafficking through the secretory pathway (33).  
We find a reduction in the Mr of all LULL1 constructs present in whole cell extracts 
(Figure 3.8C).  Because any cytosolic LULL1 constructs are expected to exist as a 
smaller, EndoH resistant species, this result suggests that our LULL1 constructs are 
correctly localized to the ER (Figure 3.8C).  Importantly, this analysis is mainly needed 
for inactive retargeting ‘off’ constructs; active LULL1 constructs must be correctly 
oriented to target ΔE torsinA to the NE.  Other constructs (myc-GCN4 MYA1 208, myc 
MYA1 LULL1) were coexpressed with GFP E171Q torsinA and qualitatively assessed 
for their ability to displace E171Q torsinA to the ER (not shown).   
Discussion 
LULL1 functions in the ER 
LULL1 activity is required for ΔE torsinA accumulation at the INM (Figure 2.3A-B), but 
LULL1 appears to remain ER-localized.  However, previous studies have not addressed 
whether a small subset of ‘active’ LULL1 could be present at the INM (14).  When 
LULL1 is restricted to the main ER system, and unable to access the INM, it retains the 
ability to target ΔE torsinA to the INM (Figure 3.2A-C). Furthermore, our data suggests 
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that a subset of LULL1 does not relocalize to the INM, even when ΔE torsinA is 
retargeted there (Figure 3.1A-D).  We also analyzed an INM directed luminal LULL1 
construct to test whether LULL1 could function at the INM (Figure 3.3A-C).  However, 
we have identified that luminal LULL1 is not able to target ΔE torsinA (Figure 3.5A-C); 
so our results that LAP1nuc-luminal LULL1 fusion protein does not target ΔE torsinA 
are not interpretable.  However, overexpression of this construct causes saturation of its 
INM binding sites (lamin binding domain) and the construct partially localizes in the bulk 
ER system.  Thus, this construct is correctly localized for an ER-based LULL1 function, 
and represents another heterologous protein fragment fused to the luminal domain of 
LULL1.  Interestingly, the LAP1 nucleoplasmic fragment is not able to complement for 
the cytosolic domain of LULL1.  This argues against the idea that any heterologous 
fragment can provide full LULL1 functionality; and suggests that ‘active’ protein 
fragments have a characteristic in common (explored in Chapter 4).   
An ER-based LULL1 activity narrows our potential hypothesizes for the mechanism of 
LULL1 activity.  For example, ER-active LULL1 cannot act as an INM anchor for ΔE 
torsinA, and it is unlikely that LULL1 can physically shuttle torsinA from the bulk ER 
system to the INM.  However, it seems plausible that ER-active LULL1 ‘modifies’ 
torsinA, either by changing the conformation of the monomeric protein, or altering its 
oligomeric state (14).  Fluorescence recovery after photobleaching (FRAP) data and Blue 
Native-PAGE analysis suggests that torsinA forms a higher order structure in the bulk 
ER, but such a large complex would not be able to enter the INM (14).  Thus, LULL1 
might ‘ratchet’ apart an ER-localized torsinA complex to allow access to the INM, the 
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site of torsinA activity.  Additional work is needed to address the specific mechanism of 
LULL1 function.   
Analysis of LULL1 domains and potential phosphorylations 
We broadly analyzed the domains of LULL1, and our results suggest that the function of 
LULL1 requires the full-length protein.  Because LULL1 is a transmembrane protein, it 
might transduce signals from the cytosol to torsinA in the ER lumen.  We hypothesized 
that the cytosolic domain might be important because it allows LULL1 to be dynamically 
regulated by differential phosphorylation.  However, mutation of several predicted 
phosphorylation sites conserved between mouse and human LULL1 did not abrogate ΔE 
torsinA targeting ability (Figure 3.6A-C).  None of our tested mutants affects LULL1 
function; additional mutagenesis data from the Hanson lab supports this finding (Hanson 
lab, personal communication).  Taken together, this suggests that LULL1 mediated ΔE 
torsinA NE accumulation may be less sensitive to downregulation of phosphorylation.  
However, modulation of the cytosolic domain cannot be ruled out as a possible regulatory 
element of LULL1 function.  Furthermore, our analysis only tests if phosphorylation 
activates LULL1 function; instead, phosphorylation modifications could inhibit LULL1 
activity, and this possibility remains untested.  Thus, mutation of phosphorylated residues 
to alanine could over-activate LULL1, but we could test whether phosphorylations have a 
role in LULL1 inhibition by mutating predicted sites to glutamate, which mimics 
constitutive phosphorylation (19). 
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Multiple heterologous fragments complement for loss of the LULL1 
cytosolic domain 
As we performed our ER-restriction analysis (Chapter 2), we added the CMPK domain to 
luminal LULL1, which lacks the cytosolic domain.  We expected this construct to be 
inactive.  However, we found that the CMPK-luminal LULL1 fusion protein could 
strongly target GFP-ΔE torsinA to the NE (Figure 3.7A).  Because of our unexpected 
results, we generated chimeras with two unrelated protein fragments, GST and GCN4-
MYA1.  We verified that our constructs were correctly oriented by testing their ability to 
relocalize NE-locked GFP-E171Q torsinA to the bulk ER (Figure 3.8A-B).  All of the 
heterologous protein fragments we tested were capable of fully complementing for the 
cytosolic domain, except for the LAP1nuc and LBR protein fragments (Figure 3.3A-C; 
Figure 3.7A-C).  Furthermore, both mouse and human LULL1 can target ΔE torsinA to 
the NE, but their cytosolic domains are only 50% similar (Figure 3.6A).  Also, previous 
yeast-2-hybrid assays (unpublished; Rose Goodchild), as well as recent work from the 
Hanson lab, have failed to detect any binding partners that interact with the cytosolic 
domain of LULL1 (Hanson lab, personal communication).  Considered together, this 
implies that the LULL1 cytosolic domain may have a more general function, instead of a 
specific cytosolic interacting partner.  There are several possibilities for a general 
function of the LULL1 cytosolic domain.  The cytosolic domain may stabilize LULL1, 
but this seems unlikely, because luminal LULL1, which lacks the cytosolic domain, is 
visualized at similar levels in situ (Figure 3.5A) and after western blotting SDS-PAGE 
separated samples (Figure 3.8C). The cytosolic domain has been hypothesized involved 
in regulated degradation of LULL1 (14), although this possibility remains untested.  The 
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chimeric constructs could be functional because they downregulate the normal turnover 
of LULL1.  However, full length LULL1 is expressed at higher levels than the chimeric 
constructs, which seems to make this hypothesis unlikely (personal observations).  
Furthermore, because all of the tested ‘active’ heterologous fragments are expected to 
form higher order structure, it is attractive to hypothesize that the cytosolic domain may 
mediate LULL1 multimerization.  We continue to investigate the behavior of the luminal 
LULL1 chimeric constructs in Chapter 4.   
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Figure 3.1: ER-localized LULL1 activity is required to retarget ΔE torsinA to the 
NE 
A.  Images show anti-myc labeling (left panel), anti-lamin B labeling (middle) and 
merged images (right panel) of CHO cells transfected with myc LULL1 after either 
selective plasma membrane permeabilization using digitonin (top) or complete membrane 
permeabilization using Triton X100 (bottom).  B. Bars show the mean ± s.e.m. of the 
ratio of NE-localized/ER-localized myc-LULL1 after permeabilization with either 
TritonX100 or digitonin.  Ratios are separately generated for cells with NE-localized and 
ER-localized myc-LULL1.  Student’s Two-Tailed T-test indicated no significant 
difference between these two conditions.  C. Images show anti-myc labeling (left panel), 
anti-GFP labeling (second panel), anti-laminB labeling (third panel) and merged images 
(right panel) of CHO cells co-transfected with myc-LULL1 and GFP-ΔE torsinA.  
Although digitonin selectively permeabilizes the plasma membrane, and does not 
permeabilize the ER membranes, the ONM is partially digitonin-sensitive, thus GFP-
labeling of luminal GFP-ΔE torsinA is possible.  D. Bars show the mean ± s.e.m. of the 
ratio of NE-localized/ER localized myc-LULL1 after permeabilization with either Triton 
X100 or digitonin.  Only cells showing NE-localized GFP-ΔE torsinA were included in 
this analysis.  Cells were selected at random and ratios were generated for cells with NE-
localized and ER-localized myc-LULL1.  Student’s Two-Tailed T-test indicated no 
significant difference between these two conditions.  Abbreviations: TX100 = Triton 
X100. Scale bar represents 10μm.  
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Figure 3.2: ER-restricted LULL1 constructs target GFP-∆E torsinA to the NE 
A.  Images show anti-GFP labeling (left panel), anti-myc labeling (middle) and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and a LULL1 
chimeric construct with an ER restriction domain.  B. Schematics showing the domain 
organization of full length LULL1 and ER-restriction constructs myc-CMPK LULL1 and 
myc MYA1 LULL1.  The red box represents c-myc epitope tags used for construct 
visualization.  C. Bars show the mean ±s.e.m. of the ratio of NE-localized / ER-localized 
GFP-ΔE torsinA after co-expression with a LULL1 construct.  Cells were selected 
randomly for analysis.  **** indicates cells where ΔE torsinA concentrates in the NE 
after co-expression with a LULL1 construct (more NE labeling) compared to co-
expression with control FLAG-CHL (N=20 cells per condition;  p<0.0001).  One Way 
ANOVA with Bonferroni Post Hoc analysis.  Scale bar represents 10μm.   
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Figure 3.3: INM-directed myc-LAP1nuc-208 LULL1 does not retarget GFP-ΔE 
torsinA  to the NE 
A.  Images show anti-GFP labeling (left panel), anti-myc labeling (middle) and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and a LULL1 
chimeric construct with an INM restriction domain.  B. Schematics showing the domain 
organization of full length LULL1 and INM-restriction construct myc-LAP1nuc-208 
LULL1.  The red box represents c-myc epitope tags used for construct visualization.  C. 
Bars show the mean ±s.e.m. of the ratio of NE-localized / ER-localized GFP-ΔE torsinA 
after co-expression with a LULL1 construct.  Cells were selected randomly for analysis.  
**** indicates cells where ΔE torsinA concentrates in the NE after co-expression with 
myc-LULL1 (more NE labeling) versus expression with LAP1nuc-luminal LULL1 or 
control FLAG-CHL (N=20 cells per condition;  p<0.0001).  One Way ANOVA with 
Bonferroni Post Hoc analysis.  Scale bar represents 10μm.   
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Figure 3.4: The luminal torsinA interacting domain of LULL1 is required to target 
GFP-∆E torsinA to the NE 
A.  Images show anti-GFP labeling (left panel), anti-myc labeling (middle) and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and truncation 
mutant myc 1-208 LULL1 (top), myc-LULL1 (middle) or control membrane protein 
FLAG-CHL (bottom).  B. Schematic showing the domains of full length LULL1 and 
truncation mutant myc-1-208 LULL1. The red box represents c-myc epitope tags used for 
construct visualization.   C. Bars show the mean ± s.e.m. of the ratio of NE-localized/ER 
localized GFP-ΔE torsinA after co-expression with a LULL1 construct.  Cells were 
selected randomly for analysis.  **** indicates cells where ΔE torsinA concentrates in the 
NE after co-expression with myc-LULL1 (more NE labeling) versus expression with the 
cytosolic fragment of LULL1 or control FLAG-CHL (N=20 cells per condition; 
p<0.0001).  One way ANOVA with Bonferroni Post Hoc analysis.  Scale bar represents 
10μm.  
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Figure 3.5: The cytosolic domain of LULL1 is required to retarget GFP-∆E torsinA 
to the NE 
A. Images show anti-GFP labeling (left panel),anti-myc labeling (middle), and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and myc-LULL1 
or truncation mutant myc-208 LULL1.  B. Schematic showing the domains of full length 
LULL1 and truncation mutant myc-208-LULL1.  The red box represents c-myc epitope 
tags used for construct visualization.  C. Bars show the mean ±s.e.m. of the ratio of NE-
localized / ER-localized GFP-ΔE torsinA after co-expression with a LULL1 construct.  
Cells were randomly selected for analysis.  **** indicates cells where ΔE torsinA 
concentrates in the NE after co-expression with myc-LULL1 (more NE labeling) versus 
co-expression with the luminal fragment of LULL1 or control FLAG-CHL ( N=20 cells 
per condition; p<0.0001).  One Way ANOVA with Bonferroni Post Hoc analysis.  Scale 
bar represents 10μm.  
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Figure 3.6: LULL1 activity is unaffected by mutation of predicted cytosolic domain 
phosphorylation sites 
A. Images show anti-GFP labeling (left panel), anti-myc labeling (middle), and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and mouse full 
length LULL1 (top) or human full length LULL1 (bottom).  B. Images show anti-GFP 
labeling (left panel), anti-myc labeling (middle) and merged images (right panel) of CHO 
cells co-transfected with GFP-ΔE torsinA and a myc-LULL1 mutant.  C. Schematic 
showing the approximate location of mutated putative phosphorylated residues in 
constructs T66A/S70A/S7A, S120A/S122A, and S163A/S167A.  The red box represents 
c-myc epitope tags used for construct visualization.  Scale bar represents 10μm.  
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Figure 3.7: Multiple heterologous protein fragments can complement for loss of the 
required cytosolic domain 
A. Images show anti-GFP labeling (left panel), anti-myc labeling (middle), and merged 
images (right panel ) of CHO cells co-transfected with GFP-ΔE torsinA and myc-208 
LULL1 chimeric constructs.  B. Schematics showing the domain organization of full 
length LULL1 and chimeric myc-208 LULL1 constructs myc CMPK 208 LULL1, myc 
GCN4-MYA1 208 LULL1 and myc GST 208 LULL1.  The red box represents c-myc 
epitope tags used for construct visualization.  D. Bars show the mean ± s.e.m. of the ratio 
of NE-localized / ER-localized GFP-ΔE torsinA after co-expression with a LULL1 
construct. FLAG CHL is a control membrane protein that does not interact with torsinA.  
**** indicates cells where ΔE torsinA concentrates in the NE after co-expression with a 
myc-LULL1 construct (more NE labeling) versus expression with control FLAG-CHL ( 
N=20 cells per condition; p<0.0001).  One Way ANOVA with Bonferroni Post Hoc 
analysis.    Scale bar represents 10μm.  
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Figure 3.8: NE-localized GFP-E171Q torsinA is displaced by ER-resident LULL1 
constructs 
A. Images show anti-GFP labeling (left panel), anti-myc labeling (middle), and merged 
images (right panel) of CHO cells co-transfected with GFP-E171Q torsinA and myc-
LULL1 constructs.  B. Bars show the mean ± s.e.m. of the ratio of NE-localized / ER-
localized GFP-E171Q torsinA after co-expression with a LULL1 construct. FLAG CHL 
is a control membrane protein that does not interact with torsinA. Ratios are separately 
generated for cells with NE-localized and ER-localized E171Q torsinA. **** indicates 
cells where E171Q torsinA is displaced to the ER after co-expression with a LULL1 
construct (less NE labeling)( N=20 cells per condition; p<0.0001) compared to co-
expression with FLAG-CHL, where E171Q torsinA remains NE localized.  One Way 
ANOVA with Bonferroni Post Hoc analysis.  C.  Glycosylation state of LULL1 test 
constructs assessed by SDS-PAGE and anti-myc western blotting of 25ug of 1% SDS 
extracted HEK293 lysates transfected with LULL1 constructs that were mock treated (-) 
or digested with EndoH (+).  Scale bar represents 10μm.  
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CHAPTER 4 : DIMERIZATION OF LULL1 MAY BE REQUIRED TO 
TARGET ΔE TORSINA TO THE INM 
 
Introduction 
Paradoxically, we found that the cytosolic domain of LULL1 was required to retarget ΔE 
torsinA to the NE, yet truncation of the cytosolic domain could be fully complemented by 
multiple heterologous protein fragments (Chapter 3).  A review of the literature suggests 
that each ‘active’ heterologous protein fragment is capable of forming higher order 
structure (18, 37).  It is possible that LULL1 activity, and ΔE torsinA NE targeting, is 
dependent on LULL1 multimerization.  We tested whether full-length LULL1, as well as 
active chimeric luminal LULL1 constructs, form higher order structure using Blue-Native 
PAGE.  We also investigated whether point mutations could abolish dimerization ability 
of the GST-luminal LULL1 chimeric protein, and thus prevent ΔE torsinA relocalization 
to the NE.   
Furthermore, we designed a series of experiments that could directly test whether 
dimerization of the LULL1 cytosolic domain underlies its significance by using the 
iDimerize Inducible Homodimerization kit (Clontech).  The kit exploits the DmrB 
binding domain, which is fused to a protein of interest, in our case, the luminal domain of 
LULL1.  DmrB interacts with a cell-permeable ligand B/B, which induces DmrB 
domains to interact, and leads to controllable homodimerization of the of the DmrB 
chimeric protein.  Our previous data (Chapter 3) revealed that luminal LULL1 is inactive, 
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but the addition of an unrelated heterologous domain could complement for loss of the 
cytosolic domain.  Now, we will test whether addition of the DmrB domain, and 
induction of homodimerization, will ‘turn on’ LULL1 mediated targeting of ΔE torsinA 
to the NE.     
Methods 
Plasmid generation 
All constructs were cloned into pcDNA 3.1.  PCR product generation and Quikchange 
was performed as previously described (Chapter 2).  The DmrB domain was amplified 
from the pHom-1 plasmid using TTTGCTAGCGCTTCTAGAGGAGTGCAGGTG and 
GTAGTCTGGTACGTCGTACGG primers and ligated into the luminal LULL1 (myc-
208 LULL1) sequence using the NheI restriction site.  A tandem c-myc tag was ligated at 
the NheI site as described in Chapter 2. To generate myc-GST 208 LULL1 mutants, PCR 
mutagenesis was performed to mutate codon 52 to alanine (F52A) and codon 73 to 
glutamate (R73E, F52A/R73E) in the GST sequence of the construct myc-GST 208 
LULL1.   
 
Cell culture, transfections, immunolabeling, and quantification 
Cell culture, transfections and immunolabeling were performed essentially as described 
in Chapter 2. 
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DmrB homodimerization of myc-DmrB 208 LULL1 
We empirically determined conditions for DmrB homodimerization induction using cells 
transfected with GFP-ΔE torsinA and myc-DmrB 208 LULL1.  We used both live-cell 
imaging of intrinsic GFP fluorescence or fixed cells labeled for immunofluorescence 
visualization.  We observed cells after no treatment with B/B homodimerization ligand, 
or treatment with increasing concentrations of B/B (10nM, 30nM, 300nM, 500nM).  We 
found that overnight incubation with 10nM B/B represented optimal treatment time to 
observe NE accumulation of GFP-ΔE torsinA and these conditions were used our 
quantifications.  
Co-immunoprecipitation 
Confluent dishes of CAD cells transfected with GFP-LULL1, pYFP, or GFP-E171Q 
torsinA were collected, pelleted and solubilized in MPER containing 3mM ATP, 2mM 
MgCl2, protease inhibitors (1X protease inhibitor cocktail (Sigma), 2mM PMSF), and 
phosphatase inhibitors (5mM molybdate, 30mM β-glycergophosphate, 10mM sodium 
fluoride).  We removed insoluble material by centrifugation at 20 000 x g, and incubated 
soluble lysates for 20 min at 4°C with anti-GFP antibody, followed by incubation with 
Protein A agarose for 2.5 h.  Next, we washed the agarose resin twice with solubilization 
buffer and eluted the captured proteins by incubation with non-reducing 2X Laemmli 
buffer.  Elutes and lysates were analyzed using standard SDS-PAGE and western blotting 
procedures.   
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Blue Native PAGE 
Blue Native PAGE (BN-PAGE) was performed essentially as described in (38).  
Transfected CHO cells were collected by centrifugation (900g for 5 min) and solubilized 
for 20 min in BN-PAGE buffer (0.5% digitonin, 50mM imidazole pH 7.0, 50mM NaCl, 
4mM MgCl2, 2mM ATP, 2mM 6-aminocaproic acid (Fisher), 1mM PMSF and 1 X 
protease inhibitor cocktail).  Insoluble material was removed by centrifugation at 20000g 
for 10 min, followed by ultracentrifugation at 100000g for 30 min.  Protein 
concentrations were determined using the Bradford protein assay (Biorad); 25ug of total 
protein were loaded per lane.  25ug of total protein for each sample was also separated by 
SDS-PAGE to determine relative expression levels for each construct.  Following BN-
PAGE or SDS-PAGE, samples were analyzed using anti-myc Western blotting under 
standard conditions.  
Results 
Blue-Native PAGE 
Monomeric myc-LULL1 has a Mr of 70kDa when separated on SDS-PAGE. 
Overexpressed myc-LULL1 reproducibly separates into a Mr ~146kDa band on Blue-
Native PAGE, consistent with the formation of a dimeric species (Figure 4.1A).  
Furthermore, inactive luminal LULL1 (myc-208 LULL1) separates into a Mr~30kDa 
band, consistent with a monomeric species (Figure 4.1A).  We have tested whether two 
different luminal LULL1 chimeras, myc-GST-208 LULL1 and myc-CMPK-208 LULL1, 
can form higher order structure.  We find that these ‘active’ chimeric fusions appear to 
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multimerize, and form species with a higher Mr than expected for a dimeric species  
(Figure 4.1A and C).  Expression levels were verified by simultaneous SDS-PAGE 
(Figure 4.1B and D).  Our data associates multimerization ability with LULL1 activity, 
but we cannot conclude that oligomerization is the sole function of the LULL1 cytosolic 
domain.   
Co-immunoprecipitation of endogenous LULL1 using GFP-LULL1 
We tried to detect self-association of LULL1 using co-immunoprecipitation analysis.  For 
our study, we overexpressed GFP-LULL1 and attempted to detect interaction with 
endogenous LULL1.  As a negative control, we separately overexpressed pYFP, which 
does not interact with LULL1.  For a positive control, we overexpressed GFP E171Q 
torsinA, which has a strong interaction with LULL1 (5).  A positive result would show 
simultaneous capture of GFP-LULL1, with pulldown of endogenous LULL1.  We find 
that positive control GFP E171Q torsinA captured endogenous LULL1 (Figure 4.2A, 
right panel).  However, despite capture of GFP-LULL1, we failed to detect a stable 
interaction (Figure 4.2A-B).   
GST point mutations do not abolish ΔE torsinA NE targeting 
Our results associate multimerization with the ability of chimeric constructs to target ΔE 
torsinA to the NE.  Thus, if our hypothesis is correct, we expect that monomeric 
constructs would be inactive.  GST is a well-studied protein domain, so our mutagenesis 
analysis focused on our GST-luminal LULL1 chimeric construct (myc-GST-208 
LULL1).  The GST-luminal LULL1 fusion protein has been shown to oligomerize 
(Figure 4.1A), and robustly targets ΔE	  torsinA	  to	  the	  NE	  (Chapter	  3).	  	  Furthermore,	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the	  isolated	  GST	  domain	  has	  been	  shown	  to	  homodimerize	  in	  solution	  (37).	  	  We 
designed a mutagenesis strategy to push the GST domain on our chimeric construct 
toward a monomeric equilibrium.  We based our strategy on previously published work 
on the biochemical characteristics of GST point mutations in solution (37).  Single 
mutants F52A and R73E have been shown to shift equilibrium from a predominantly 
dimeric WT species to monomeric species (37).  We generated mutants F52A, R73E, and 
the double mutant F52A/R73E in the background of myc-GST 208 LULL1(Figure 4.3A).  
Our analysis utilized our cell-based overexpression strategy, described previously 
(Chapters 2 and 3).  We find that the single mutants are capable of retargeting GFP-ΔE 
torsinA, although previous biochemical studies have established that these single mutants 
are adequate to ‘trap’ GST in a monomeric state in solution.  Thus, we hypothesize that 
our single mutants may not be sufficient to remove dimerization ability in vivo (Figure 
4.3A, top and middle panels).  The double mutant F52A/R73E did not retarget GFP-ΔE 
torsinA to the NE; GFP-ΔE signal remains equally distributed between the NE and main 
ER (Figure 4.3A, bottom panel).  However, anti-myc immunofluorescence detecting the 
c-myc-tagged F52A/R73E construct showed much lower signal than expected, and we 
verified our immunofluorescence result using western blotting to detect protein 
expression levels (Figure 4.3B, compare expression levels of myc-GST-208 LULL1 and 
myc GST F52A/R73E 208-LULL1).  The F52A/R73E double mutant is unable to target 
GFP-ΔE torsinA to the NE, but we cannot dissect whether inactivity is due solely to poor 
expression and/or inability to dimerize.    
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DmrB-luminal LULL1 can be induced to retarget ΔE torsinA  
Using the iDimerize kit, we generated a chimeric fusion protein with the DmrB domain 
and the luminal domain of LULL1 (myc-DmrB-208 LULL1) (Figure 4.4A-B).  Cells 
cotransfected with inactivated myc-DmrB 208 LULL1 and GFP-ΔE torsinA show equal 
distribution of GFP-ΔE torsinA between the NE and main ER system.  However, 
inactivated DmrB-luminal LULL1 appears mislocalized to the plasma membrane (Figure 
4.4A, bottom panel).  We also found a high number of cells with inactivated DmrB-
luminal LULL1 mislocalization to the Golgi.  However, after treatment with B/B 
homodimerization ligand, we find that DmrB-luminal LULL1 appears to be correctly 
localized to the ER; furthermore, ΔE torsinA is strongly relocalized to the NE (Figure 
4.4A, top panel).  As a control, we coexpressed ER-localized control membrane protein 
FLAG-CHL, which does not interact with GFP-ΔE torsinA.  Cells cotransfected with 
FLAG-CHL did not retarget GFP-ΔE torsinA to the NE, and resulted in diffuse GFP-ΔE 
torsinA signal distributed between the NE and bulk ER, with a NE/ER ratio of GFP-ΔE 
fluorescence intensity with a mean ± s.e.m. of 0.97 ± 0.02 (n=20).  Coexpression of GFP-ΔE torsinA and DmrB-luminal LULL1, incubated overnight with 10nM of B/B, resulted 
in strong GFP-ΔE NE accumulation, with a relative NE/ER ratio of GFP-ΔE fluorescence 
intensity with a mean ± s.e.m. of 1.584 ± 0.06 (n=20) (Figure 4.4C).  We tested whether 
incubation with B/B ligand stabilizes DmrB-luminal LULL1 using western blotting of 
cells expressing inactivated DmrB-luminal LULL1 or after overnight incubation with 
B/B (Figure 4.4D.)  We find that the inactivated DmrB-luminal LULL1 appears partially 
degraded, while the B/B treated sample separates into a distinct band (Figure 4.4D).  If 
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inactivated DmrB-luminal LULL1 is secreted to the plasma membrane, as our 
immunofluorescence data suggests, the luminal LULL1 domain would be exposed to the 
extracellular domain, and partially degraded by trypsin when the cells are collected for 
analysis.  Thus, this data supports our hypothesis that inactivated DmrB-luminal LULL1 
enters the secretory pathway, and transported out of the bulk ER system.     
Discussion 
Co-immunoprecipitation of LULL1 and BN-PAGE of LULL1 constructs 
We find that both full-length LULL1 and active LULL1 chimeric fusions assemble into 
higher order structure (Figure 4.1A and C).  Each active construct separates into a Mr 
band consistent with formation of a dimer or multimeric structure.  Importantly, we find 
that active constructs show no signal at a Mr consistent with a monomeric species, even 
after long western blotting exposures.  On the other hand, inactive luminal LULL1, which 
lacks the cytosolic domain, separates at Mr consistent with a predominantly monomeric 
species (Figure 4.1A).  Our data suggests that the LULL1 cytosolic domain contributes to 
dimerization of full length LULL1, and certain heterologous domains can complement 
for truncation of the cytosolic domain because they mediate multimerization of the 
luminal LULL1 domain.  However, several lines of evidence suggest that both the 
cytosolic and luminal domains are required for LULL1 dimerization in vivo.  We suggest 
that ‘active’ heterologous protein fragments are permissive to luminal LULL1 
dimerization.  Thus, if a cytosolic heterologous protein fragment is disruptive to luminal 
LULL1 interaction (strongly promotes monomerization), it will not complement for the 
cytosolic domain of LULL1.  We hypothesize that the inactive DmrB domain is 
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disruptive to luminal LULL1 interaction, and thus this construct is not able to promote 
ΔE torsinA NE concentration.   
We attempted to detect self-interaction of LULL1 using immunoprecipitation analysis, 
but we failed to detect a stable association (Figure 4.2A-B).  Importantly, the GFP-
LULL1 construct used in this study is tagged with a GFP domain that can form 
homodimers; thus, it is possible that the GFP tag on LULL1 strongly homodimerizes, and 
the construct self-interacts, and fails to stably associate with endogenous LULL1.  This 
result does not preclude self-interaction; importantly, the Hanson group has successfully 
co-immunoprecipitated endogenous LULL1 using a LULL1-mGFP construct with a 
monomeric GFP tag; they have also successfully co-immunoprecipitated myc-LULL1 
with LULL1-mGFP (Hanson lab, personal communication).   
DmrB-luminal LULL1 
To test directly whether dimerization underlies the importance of the cytosolic domain, 
we generated a chimera using the DmrB homodimerization domain and the luminal 
domain of LULL1 (myc-DmrB 208 LULL1).  We expected that DmrB-luminal LULL1 
would be ER-localized, but unable to target ΔE torsinA to the INM unless 
homodimerization was activated by the B/B ligand.  We find that treatment with B/B 
ligand promotes strong GFP-ΔE torsinA relocalization to the NE (Figure 4.4A).  
Considered with our other results, our data builds a strong association between 
oligomerization and LULL1 activity; however, we cannot conclude that the cytosolic 
domain solely mediates dimerization of LULL1.  Importantly, our results could also be 
explained by oligomerization that promotes increased ER-retention of LULL1.   
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Strangely, control cells, co-expressing GFP-ΔE torsinA and DmrB-luminal LULL1, but 
without B/B ligand treatment, showed significant mislocalization of the construct to the 
Golgi (not shown) and plasma membrane (Figure 4.4A, compare upper and lower 
panels).  It appears that inactivated DmrB-luminal LULL1 enters the secretory pathway 
and travels out of the bulk ER system.  However, after overnight incubation with B/B 
ligand, we find that DmrB-luminal LULL1 is predominantly localized in the bulk ER, 
and ΔE torsinA is strongly accumulated in the INM (Figure 4.4A, compare upper and 
lower panels).  Furthermore, without B/B present, DmrB-luminal LULL1 appears 
partially degraded on SDS-PAGE.  Plasma membrane localization of this construct would 
expose the luminal domain to the extracellular environment; and thus expose it to partial 
degradation by trypsin when the cells were collected for analysis.  However, when cells 
are incubated with B/B, the construct separates into a distinct Mr band, suggesting that 
the construct is now protected from degradation.  These results are consistent with our 
immunofluorescence images.  
The underlying cause for the mislocalization of the inactivated construct is unclear, but 
we suspect that increasing the size of the construct after B/B mediated homodimerization 
helps to correctly retain the construct in the ER.  Notably, the predominantly monomeric 
luminal LULL1 construct consistently shows a very high molecular weight band on BN-
PAGE (Figure 4.1A), and this high molecular weight species may contribute to the 
correct ER-retention of the construct, without facilitating LULL1 function and ΔE 
torsinA relocalization.  Taken together, we hypothesize that inactivated DmrB-luminal 
LULL1 may be a truly monomeric construct that can more efficiently enter the secretory 
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pathway compared to our other constructs that form robust higher-order structure.  
However, other reasons for mislocalization of the construct are possible.  Assuming that 
all of our cloning strategies are correct, the DmrB domain may have an intrinsic ER-
export signal, which is hidden after dimerization of the construct, so that B/B treatment 
causes the construct to be retained in the bulk ER.  Furthermore, the diacidic residues 
present on the N-terminal c-myc epitope tag could contribute to export of the construct 
(Hanson lab, personal communication).  Because of the instability and mislocalization of 
the inactivated DmrB-luminal LULL1 construct, work is ongoing to generate new 
chimeras between DmrB and the luminal domain of LULL1.  At this point, we cannot 
conclude that the cytosolic domain solely mediates multimerization, or that dimerization 
is the sole factor underlying LULL1 function; our data could also support an increase in 
protein localization, ER levels, or stability as a factor required for LULL1 activity.  
Additional work, especially BN-PAGE analysis of this construct, is required to confirm 
our hypotheses. 
Thus far, our study has focused on how torsinA is targeted to the NE.  Both the normal 
function of torsinA, as well as the dysfunction of the ΔE isoform, center at the NE, but 
but the function of NE-directed torsinA AAA+ activity is unknown.  In the next chapter, 
we will set the foundation for an in vitro system that can be used to analyze the torsinA 
AAA+ biochemical mechanism, as well as the effect of the ΔE deletion on normal protein 
function.  
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Figure 4.1: Full length LULL1 and active chimeric LULL1 constructs form 
multimeric species on BN-PAGE 
A. Anti-myc western blotting of BN-PAGE separated CHO cell lysates detects 
oligomeric myc-LULL1 and myc-GST 208 LULL1, although myc-208 LULL1 remains 
predominantly monomeric.  Coomassie staining of BN-PAGE separated Native Mark 
protein standards (Invitrogen) determined the Mr of BN-PAGE separated samples. B. 
Anti-myc western blotting of SDS-PAGE separated CHO cell lysates.  Equal amounts of 
CHO lysate expressing myc-LULL constructs were separated on BN-PAGE (A) or SDS-
PAGE (B) to check expression levels of each construct.  Precision Plus Protein Prestained 
standards (Biorad) identified myc LULL1 proteins by Mr after SDS-PAGE separation.  
C. Anti-myc western blotting of BN-PAGE separated CHO cell lysates detects 
oligomeric myc-LULL1, myc-CMPK 208 LULL1, and myc-CMPK LULL1.  Coomassie 
staining of BN-PAGE separated Native Mark protein standards (Invitrogen) determined 
the Mr of BN-PAGE separated samples. D. Anti-myc western blotting of SDS-PAGE 
separated CHO cell lysates.  Equal amounts of CHO lysate expressing myc-LULL 
constructs were separated on BN-PAGE (C) or SDS-PAGE (D) to check expression 
levels of each construct.  Precision Plus Protein Prestained standards (Biorad) identified 
myc LULL1 proteins by Mr after SDS-PAGE separation. 
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Figure 4.2: A stable interaction between endogenous LULL1 and GFP-LULL1 is 
not detectable by co-immunoprecipitation 
A. Left panel shows anti-LULL1 western blotting of 1% of total CAD cell extract before 
(pre-IP; input) and after (post-IP; capture) anti-GFP immunoprecipitation.  Right panel 
shows that despite expression, endogenous LULL1 does not co-immunoprecipitate with 
GFP-LULL1 or negative control pYFP, but does immunoprecipitate with positive control 
GFP E171Q torsinA.  B. Left panel shows anti-GFP western blotting of 1% of total CAD 
cell extract before (pre-IP; input) and after (post-IP; capture) anti-GFP 
immunoprecipitation and demonstrates that the majority of expressed GFP-E171Q 
torsinA, pYFP, and GFP-LULL1 are captured (right panels).  Due to the high sensitivity 
of anti-GFP western blotting, some images are very dark.  
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Figure 4.3: Single GST mutants F52A and R73E -208 LULL1 target GFP-ΔE 
torsinA to the NE, but inactive double mutant GST F52A/R73E-208 LULL1 is 
poorly expressed 
A. Images show anti-GFP labeling (left panel), anti-myc labeling (middle), and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and a myc-GST 
208 LULL1 mutant.  B. Anti-myc western blotting of SDS-PAGE separated CHO cell 
lysates expressing either myc-GST-208 LULL1 or double mutant myc GST F52A/R73E 
208 LULL1.  Precision Plus Protein Prestained standards (Biorad) identified myc LULL1 
proteins by Mr after SDS-PAGE separation.  Scale bar represents 10μm.  
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Figure 4.4: Addition of B/B homodimerizer ligand stabilizes DmrB luminal LULL1 
and redirects GFP-ΔE torsinA to the NE 
A. Images show anti-GFP labeling (left panel), anti-myc labeling (middle), and merged 
images (right panel) of CHO cells co-transfected with GFP-ΔE torsinA and myc-DmrB 
208 LULL1 after overnight treatment with 10nM B/B ligand (top) or without treatment 
(bottom).  B. Schematic showing the domain organization of myc-DmrB 208 LULL1.  C.  
Bars show the mean ± s.e.m. of the ratio of NE-localized / ER-localized GFP-ΔE torsinA 
after co-expression with a LULL1 construct. Cells were selected randomly for analysis. 
**** indicates cells where ΔE torsinA concentrates in the NE after co-expression with 
B/B treated DmrB-luminal LULL1 (more NE labeling) versus co-expression with control 
FLAG-CHL ( N=20 cells per condition; p<0.0001).  Student’s Two-Tailed T-test.  D. 
Anti-myc western blotting of SDS-PAGE separated CHO cell lysates expressing myc-
DmrB-208 LULL1 without treatment (left) or after overnight treatment with 10nM B/B 
ligand.  Precision Plus Protein Prestained standards (Biorad) identified myc LULL1 
proteins by Mr after SDS-PAGE separation.  Scale bar represents 10μm.  
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CHAPTER 5 : DEVELOPMENT OF AN IN VITRO TOOLKIT TO 
STUDY THE AAA+ BIOCHEMICAL CYCLE OF TORSINA 
 
Introduction 
Loss of torsinA activity results in ultrastructural abnormalities of the NE membranes (3), 
but the mechanism of torsinA AAA+ activity and the targets affected by torsinA are 
unknown.  Based on sequence analysis, torsinA has been assigned to the AAA+ enzyme 
superfamily (24), but this provides only a few clues about the exact function of torsinA.  
There are hundreds of AAA+ family members and a huge diversity of substrates and 
functions (23, 24, 39). Typical AAA+ family members form higher-order structures and 
couple the power of nucleotide binding, hydrolysis, and release to conformational change 
in protein substrates (Figure 5.1A)(23, 25, 26, 39).  However, the presence of multiple 
torsinA binding partners in the ER and INM implies that the torsinA AAA+ biochemical 
mechanism may be more complex than the basic AAA+ cycle of nucleotide binding, 
hydrolysis and release.  
Membership in the AAA+ family has specific implications on the normal function of 
torsinA, as well as the possible impact of the ΔE deletion.  Because mutant ΔE torsinA is 
present in the disease condition, these considerations are especially important.  
Conventionally, oligomerization of AAA+ family members allows mutant inactive 
  84 
subunits to co-assemble with WT subunits, which can dominant-negatively inhibit 
enzyme activity (25).  Thus, expression of inactive ΔE torsinA mutant protein may inhibit 
torsinA activity below the 50% reduction expected if the Δgag allele has only a 
haploinsufficiency effect.  However, it is equally possible that the presence of the ΔE 
isoform deletriously weakens or stabilizes a normal torsinA interaction. Previous research 
has proposed that the ΔE deletion impairs interaction with normal torsinA binding 
partners (5), but it is unclear whether known torsinA binding partners represent 
substrates, accessory partners, or both.  Establishment of an in vitro system will allow us 
to address these and other questions about the normal function of torsinA and how it is 
affected by the ΔE deletion.   
Previous biochemical, cell-free characterization of torsinA is limited to studies of the 
monomeric protein (40-42).  However, typical AAA+ family members oligomerize, and a 
hexameric form of torsinA (240kDa) can be extracted from mammalian cells with mild 
detergents (14).  This suggests that torsinA has classic AAA+ oligomerization behavior, 
and calls previous biochemical characterization of the monomeric protein into question.  
Cell free assays for many cytosolic AAA+ proteins have been developed (25, 43, 44), but 
development of cell free assay for torsinA function has been challenging for several 
reasons.  TorsinA is peripherally membrane associated through an N-terminal 
hydrophobic sequence (32, 41).  Several groups have attempted to truncate the membrane 
association domain to promote solubilization of recombinant torsinA, but all truncated 
constructs remained monomeric, which implies that the membrane association domain 
may be necessary for oligomerization (41, 42).  Furthermore, torsinA is an ER-resident 
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protein, so it functions in an environment that is very different from the cytosol.  To 
overcome these issues, we built on previous research to develop an insect cell based 
baculovirus system to express and semi-purify the full-length torsinA protein.  
Ultimately, our goal is to establish an in vitro system that can be used to assess the 
oligomeric state of torsinA, whether torsinA can hydrolyze ATP, and if the presence of ΔE torsinA poisons WT function or alters interactions with identified torsinA binding 
partners.  These experiments are difficult, but they have the ability to greatly improve our 
understanding of torsinA function.    
Methods 
Plasmid generation 
 PCR amplification used Platinum Taq high fidelity PCR (Invitrogen).  Manufacturer’s 
instructions for the Bac-to-Bac system (Invitrogen) were used to initiate recombinant 
torsinA expression in insect cells.  A construct coding for full length torsinA was 
generated using the following  primers: ATGAAGCTGGGCCGGGCCG and 
ATCATCGTAGTAAATAATCTAAC and directly TOPO cloned into the shuttle vector 
pFASTBAC TOPO (Invitrogen).  pFASTBAC TOPO constructs were fully sequenced 
and transformed into DH10Bac E.coli for bacmid generation.  TorsinA interacting 
partners were generated by PCR using for human luminal LAP1 starting at codon 95, 
human luminal LULL1  starting at codon 244 and mouse luminal SUN1 starting at codon 
1413.  PCR products were TOPO cloned into the pCR8 shuttle vector and subsequently 
cloned into a destination vector (pDEST17 or pDEST15) according to the manufacturer’s 
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instructions for the Gateway System (Invitrogen). All plasmid constructs were confirmed 
by sequencing.   
Production of recombinant baculovirus for torsinA recombinant expression 
Bacmid DNA was transfected on a 6 cm2 layer of monolayer 50% confluent spodoptera 
frugiperda (SF9) cells with 2.5 mL of serum-free insect media (Gibco SF900 II SFM), 
30uL of CELLfectin (Invitrogen) and 2-5ug of bacmid DNA.  These mixtures were 
incubated for 5 h at 28°C, and then serum-free media (2.5mL) was added and 
transfections were incubated 5-10 days in a 28° incubator.  Supernatents were harvested, 
and 100uL to 1mL was used to infect a fresh batch of cells.  Infection was observed in 3-
5 days, and expression of protein was verified by SDS-PAGE followed by western 
blotting of the lysed cell pellet with anti-torsinA antibodies.  The virus was amplified 
once 50 fold, and twice 100 fold.  Our methodology is based on previous research 
described in Kustedjo et al (40). 
 
Optimization of WT torsinA expression in baculovirus-infected SF9 cells or 
HighFive cells 
SF9 cells were infected in monolayer culture (SF900 II SFM media) and HighFive cells 
were infected in suspension culture in serum free media.  Cells were infected at a cell 
density of approximately 2-4 x 106 cells/mL.  Cells were harvested at 24h, 48h, 60h, 72h, 
or 96h hours post-infection in 5mL aliquots from a 50mL culture.  Cell pellets were 
isolated by centrifugation (1000g, 5min), and resuspended in buffer (1% TritonX100, 
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0.1M Tris-HCL pH 7.4, 250mM NaCl, 5mM EDTA) containing protease inhibitors 
(inhibitor cocktail and PMSF (Sigma)).  Cells were lysed by sonication and the cytosolic 
and membrane fractions were separated by centrifugation (21.1g, 15 min).  Aliquots of 
each cellular fraction were analyzed on SDS-PAGE followed by western blotting with 
anti-torsinA antibodies or anti-X5HIS (Qiagen).   From this analysis, it was determined 
that 54 h represented optimal post-infection period for recombinant production of 
torsinA.  Our methodology is based on previous work described in Kustedjo et al(40) 
Purification of WT torsinA from large scale cultures 
Large scale cultures of suspension HighFive cells were pelleted at 1000g for 30 min.  The 
cell pellet was washed 2 times with 10mL of phosphate buffered saline and pelleted again 
at 1000g for 15 min.  Cells were lysed in buffer (0.1M Tris-HCl, pH 7.4, 400mM 
sucrose) containing protease inhibitors (PMSF and protease cocktail (Sigma) using 
dounce homogenization (25x) and probe sonication on ice.  Cell lysate was sequentially 
centrifuged; 3000g to pellet unbroken cells, nuclei, and heavy membranes, and the 
supernatent was further ultracentrifuged at 100000g (1 h) to isolate torsinA-containing 
microsomes.  TorsinA proteins were solubilized from microsomes by homogenization 
(25x) in 20mL of buffer + 1% TX100 followed by probe sonication on ice, and rotation at 
4°C for 1 hour.  Soluble lysate was ultracentrifuged at 100000g, and the soluble fraction 
was incubated with 500uL Talon cobalt affinity resin (Clontech).  The mixture was 
incubated at 4°C for 1 h, and the beads were collected in a flex column, washed with 
25mL buffer + detergent, and eluted with 250uL aliquots of buffer + 500mM imidazole.  
The eluted fractions were analyzed by SDS-PAGE followed by staining (Coomassie 
  88 
blue) or Western blotting with anti-torsinA or anti-x5HIS antibodies.  EndoH glycosidase 
studies were performed according to the manufacturer’s instructions (New England 
Biolabs).   
Recombinant interacting partners 
Expression constructs encoding recombinant interacting partners ligated in frame with a 
GST (pDEST15) or x6HIS (pDEST17) tag were transformed into BL-21 RIPL or Rosetta 
Gami E.coli.  Recombinant	  expression	  was	  performed	  in	  BL-­‐21	  RIPL	  or	  Rosetta-­‐Gami	  E.coli	  and	  expression	  conditions	  were	  determined	  empirically	  for	  each	  construct.	  	  Typical	  expression	  conditions	  were	  induction	  at	  OD	  0.5	  with	  200mM	  IPTG	  for	  5	  hours	  at	  15°C	  or	  overnight	  at	  30°C.	  Cultures	  were	  harvested	  and	  solubility	  was	  determined	  empirically	  using	  a	  battery	  of	  solubility	  conditions,	  including	  BPER	  (Pierce),	  MPER	  (Pierce),	  1%Triton	  X100,	  and	  8M	  Urea.	  	  In	  some	  cases,	  we	  refolded	  proteins	  solubilized	  from	  inclusion	  bodies	  using	  protocols	  from	  Pierce.	  	  Recombinant	  interacting	  partners	  were	  semi-­‐purified	  using	  either	  GST-­‐agarose	  (Fisher,	  GST-­‐tagged	  constructs),	  or	  IMAC	  (Clontech,	  X6-­‐HIS-­‐tagged	  constructs).	  	  
Co immunoprecipitation studies 
Confluent dishes of NIH-3t3 cells stably expressing GFPE171Q torsinA were collected, 
pelleted and solubilized in buffer containing 3mM ATP, 2mM MgCl2, and protease 
inhibitors (1X protease inhibitor cocktail (Sigma), 2mM PMSF).  We removed insoluble 
material by centrifugation at 20 000 x g, and incubated soluble lysates for 2h at 4°C with 
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recombinant 6xHIS tagged recombinant protein, followed by incubation with 
immobilized metal affinity chromatography (IMAC) resin to capture 6xHIS tagged 
proteins.  Next, we washed the resin twice with solubilization buffer and eluted the 
captured proteins by incubation with non-reducing 2X Laemmli buffer.  Elutes and 
lysates were analyzed using standard SDS-PAGE and western blotting procedures.   
Results 
Production of torsinA expression constructs (Shuttle vectors and Bacmids) 
We used the Invitrogen Bac-to-Bac system to establish baculoviral expression of C-
terminally tagged 6XHIS torsin constructs in insect cells.  First, we produced shuttle 
vectors (TOPO pFASTBAC) encoding the full-length human DNA sequence of WT, ΔE, 
and E171Q torsinA and the full-length human DNA sequence of homologous torsin2.  
Our constructs were generated so that they were in-frame with a 6xHIS tag, which can be 
used for purification of the recombinant protein.  Our work centered on production of 
WT torsinA (Figure 5.1B).  For bacmid production, individual	  pFASTBAC	  clones	  were	  transformed	  into	  DH10BAC	  E.coli,	  and	  isolated	  constructs	  were	  verified	  using	  PCR	  (Figure	  5.1C).	  	  	  
Expression optimization and basic characterization of wild-type torsinA 
Once we had generated a recombinant WT torsinA bacmid, we established cell culturing 
protocols for SF9 and HighFive insect cell lines. SF9 cells are needed for high-level 
baculovirus production, and previous studies of recombinant torsinA solely relied on SF9 
insect cell line for protein expression (40).  However, HighFive insect cells are optimized 
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for high-level recombinant protein production, so we first wanted to establish WT 
torsinA expression in HighFive cells.  We developed reliable protocols for bacuolviral 
production using adherent cultures of SF9 cells (Figure 5.2A).  Verified bacmid 
constructs were used to transfect SF9 adherent cultures; culture media containing 
baculovirus was collected and tested for anti-torsinA immunoreactivity (Figure 5.2A-B).  
Baculovirus transduction causes SF9 cells to lyse and release virus into the media, which 
can be collected for future transductions.  Baculovirus stocks were amplified in large 
scale adherent cultures for recombinant protein expression studies.   
Adherent SF9 cultures were transduced with high titer WT torsinA baculovirus and 
harvested at 24 hours, 48 hours, 72 hours and 96 hours (Figure 5.2B).  Proteins from the 
soluble fraction were analyzed using SDS-PAGE followed by anti-torsinA western 
blotting.  These analyses identified that 56 hours represented an optimum transduction 
time for production of recombinant protein (Figure 5.2B).  We analyzed the glycosylation 
state of recombinant torsinA.  Endoglycosidase-H (EndoH) cleaves N-linked 
oligosaccarides that are added in the ER-lumen.  Because oligosaccarides become 
resistant to EndoH cleavage after enzymatic processing in the cis-Golgi, EndoH 
sensitivity can be used to assess protein trafficking through the secretory pathway (33).  
We find a reduction in the Mr of recombinant torsinA present in whole cell lysate.  
Untreated recombinant torsinA separates as three distinct bands; two bands show 
sensitivity to Endo-H treatment (Figure 5.2B).    
Next, we developed a strategy to semi-purify recombinant torsinA.  Recombinant torsinA 
has a C-terminal 6xHIS tag, so we used immobilized metal affinity chromatography 
  91 
(IMAC).  Figure 5.2C shows an example purification using WT torsinA harvested from 
HighFive cells transduced with WT torsinA baculovirus for 54 hours.  Eluted proteins 
were verified for torsinA immunoreactivity (Figure 5.2C, right panel).  
Recombinant interacting proteins and co-precipitation assays 
We extended our analysis of torsinA interactions generating E.coli expression constructs 
with the luminal domains of known interacting partners LAP1 and LULL1, and LINC 
complex component SUN1 (13, 22).  Constructs	  were	  generated	  as	  6xHIS	  or	  GST	  fusion	  proteins,	  so	  that	  the	  tag	  could	  used	  for	  semi-­‐purification	  of	  the	  constructs.	  	  We	  used	  BL-­‐21	  RIPL	  and	  Rosetta	  Gami	  E.coli,	  which	  are	  specialized	  strains	  optimized	  for	  high-­‐level	  production	  of	  recombinant	  protein.	  	  BL-­‐21	  RIPL	  E.coli	  encode	  additional	  copies	  of	  tRNA	  genes,	  and	  correct	  for	  the	  codon	  bias	  of	  E.coli,	  so	  that	  recombinant	  human	  proteins	  can	  be	  expressed	  more	  efficiently.	  Rosetta	  Gami	  
E.coli	  facilitate	  soluble	  protein	  expression	  by	  mimicking	  the	  reducing	  environment	  of	  the	  ER.	   
Figure 5.3A shows recombinant protein after expression optimization.  Luminal LULL1 
was difficult to produce in E.coli, and soluble protein was only produced when the 
construct was expressed in Rosetta Gami E.coli (Figure 5.3A, first panel).  Soluble 
luminal SUN1 was also difficult to produce, but we successfully isolated soluble protein 
after 8M Urea solubilization of inclusion bodies, followed by refolding protocols (Pierce) 
(Figure 5.3A).  Expression of the luminal domain of LAP1 reliably produced soluble 
protein in BL-21 RIPL E.coli, and we used luminal LAP1 for cell free co-precipitation 
studies (Figure 5.3A-B).  
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Cell free co-precipitation analysis shows that the recombinant luminal fragment of LAP1 
interacts with mammalian GFP E171Q torsinA (Figure 5.3B).  We mixed mammalian 
cell lysate expressing GFP E171Q torsinA with recombinant luminal LAP1, and captured 
the LAP1 with IMAC resin.  The captured luminal LAP1 co-precipitated GFP-E171Q.  
This result suggests that we can test recombinant torsinA with binding assays using 
recombinant interacting partners in the future.   
 
Discussion 
Production of recombinant torsinA 
We built on previous work to generate an in vitro system to express recombinant full-
length torsinA (40).  We completed basic characterization on the recombinant protein.  
There are two predicted glycosylation sites in the torsinA sequence (45), and after EndoH 
analysis, we find that insect expressed torsinA separates as three distinct bands on SDS-
PAGE.  We hypothesize that recombinant torsinA is present as three species: a doubly-
glycosylated, singly-glycosylated and non-glycosylated product.  Our Endo-H results are 
consistent with this analysis, and suggest that the majority of the recombinant protein is 
an ER-resident in insect cells.   
However, despite the initial success of our recombinant system, we have encountered 
several problems with protein expression and the quality of our baculoviral stocks.  We 
have previously used protein expression levels as a measure of viral titer, but this method 
does not give quantitative information about the baculoviral titer.  Future work is needed 
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to develop a reliable viral titering methodology.  These tests will allow us to 
systematically determine the titer of each viral stock so that we can ensure consistent 
expression levels.  Alternatively, other insect cell based recombinant expression systems 
are available, such as the D. melanogaster S2 expression system (46).  This alternate 
system utilizes plasmid transfections and a copper-induced promoter to drive 
recombinant protein expression, and avoids the use of potentially unstable baculoviral 
stocks(46).   
While previous studies have used truncated torsinA constructs to improve solubility (41, 
42), our studies focus on the full-length torsinA protein, which we believe more 
accurately represents the physiological behavior of torsinA(40).  However, the torsinA 
hydrophobic domain makes characterization much more difficult, as it complicates 
purification, and requires that we use detergents in each step of our analysis.  We 
hypothesize that homologous torsin family member, torsin2, which naturally lacks the N-
terminal hydrophobic domain, may be soluble in detergent-free buffer.  Although we 
have produced a shuttle vector encoding the full-length sequence of WT torsin2, we have 
not yet identified conditions for high-level protein production.   Future work with 
recombinant torsins will focus on characterization of the oligomeric state of the protein. 
Production of recombinant torsinA interacting partners  
We developed recombinant expression and purification strategies for the luminal domains 
of known torsinA interacting partners LAP1 and LULL1 (22), as well as the luminal 
domain of LINC complex component SUN1(13).  Recombinant protein fragments are 
useful for primary antibody production, and we used luminal SUN1 produced in BL-21 
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RIPL E.coli to generate anti-SUN1 antibodies used in Jungwirth et al (13).  Ultimately, 
we want to use our recombinant interacting partners in biochemical studies with torsinA.  
In a preliminary cell free assay, recombinantly expressed luminal-LAP1 co-precipitates 
with GFP-E171Q torsinA, a torsinA mutant that robustly binds to mammalian LAP1 (4, 
8).  This result suggests that recombinant luminal LAP1 is correctly folded, and useful for 
future biochemical studies.  Cell-free assays using the luminal fragment of LULL1 and 
the luminal fragment of SUN1 remain to be tested.   
Importantly, multiple studies have failed to detect a biochemical interaction between ΔE 
torsinA and LAP1, LULL1 or SUN1 (5, 27).  LAP1 does not appear to affect ΔE torsinA 
NE concentration (Chapter 2 and (13)), but both LULL1 and SUN1 contribute to ΔE 
torsinA NE localization (Chapters 2 and 3; (13)).  Thus, the relationship between ΔE 
torsinA and normal torsinA binding partners appears to be highly complex.  We suggest 
that in vivo assays, such as the overexpression paradigm we used in Chapters 2 and 3, 
currently represents the best way to test the complicated nature of the torsinA 
biochemical cycle in the future.    
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Figure 5.1: Development of a toolkit to investigate the torsinA AAA+ biochemical 
cycle 
A.  Schematic showing a typical AAA+ cycle of HSP100 subfamily enzymes, which is 
predicted to be most similar to torsinA.  HSP100 enzymes are active as hexameric, ring 
shaped structures (represented by red cylinders).  They couple repetitive cycles of ATP 
binding, hydrolysis and release to change the conformation of protein substrates 
(represented by black line).  B.  Schematic showing the shuttle vector for recombinant 
bacmid production.  The bacmid encodes full length human torsinA followed by a C-
terminal 6XHIS tag.  C. DNA agarose gel analysis of PCR verification of recombinant 
WT-torsinA bacmid production.   
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Figure 5.2: Development of recombinant torsinA expression and purification 
strategies 
A. Images showing phase-contrast visualization of control SF9 cells (top) or SF9 cells 
transduced with baculovirus (bottom).  Baculovirus transduction causes cells to lyse and 
release virus into the media, which can be collected for future transfections (bottom).  B. 
Anti-torsinA western blotting of SDS-PAGE separated SF9 cell lysate transduced with 
WT- torsinA baculovirus for 24h, 48h, 60h, 72h or 96h.  Control cells were not 
transduced with baculovirus.  C. Glycosylation state of recombinant WT torsinA assessed 
by SDS-PAGE and anti-torsinA western blotting of 25ug of 1% SDS extracted SF9 lysate 
that was mock treated (-) or digested with EndoH (+).  D. Left panel shows coomassie 
blue protein staining of SDS-PAGE separated insect cell lysate before (input) and after 
capture of 6XHIS tagged recombinant torsinA by immobilized metal affinity 
chromatography (IMAC).  Anti-torsinA western blotting of SDS-PAGE separated eluate 
verified that the eluate contained torsinA.  Precision Plus Protein Prestained standards 
(Biorad) identified torsinA proteins by Mr after SDS-PAGE separation. 
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Figure 5.3: Production of recombinant interacting partners in E.coli, and 
development of a cell-free binding assay using 6XHis-luLAP1 
A. Coomassie blue stained SDS-PAGE of recombinant torsinA interacting partners 
expressed in Rosetta Gami (luLULL1) or BL-21 RIPL (luLAP1, luSUN1) E.Coli.  B. Co-
immunoprecipitation using GFPE171Q torsinA and 6XHIS LAP1.  Panel shows anti-
GFP western blotting of 1% of stably expressing GFP E171Q torsinA NIH-3t3 cells 
before (pre-capture input, left side) and after (post-capture; right side) incubation with 
immobilized metal affinity chromatography resin (IMAC) to capture 6xHIS tagged 
proteins.  GFP E171Q cells were incubated with 6xHIS GFP or 6xHIS luLAP1, and anti-
GFP western blotting demonstrates that 6XHIS luLAP co-precipitated GFP-E171Q 
torsinA (right side) Abbreviations: lu: luminal.   
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CHAPTER 6 : CONCLUSIONS AND FUTURE WORK 
Our work has established that the disease-associated ΔE torsinA isoform mislocalizes to 
the INM subdomain of the NE, which provides clues about how the ΔE deletion could 
adversely affect neurons, the cell type implicated in DYT1 dystonia (13, 28, 29).  
Furthermore, although torsinA has been associated with several INM partners, only 
overexpression of ER-resident LULL1 alters the subcellular localization of ΔE torsinA.  
Importantly, previous analyses (as well as our own observations) have revealed that 
LULL1 overexpression also retargets WT torsinA to the NE (14).  Taken together, this 
data suggests that LULL1 may facilitate the NE-directed function of WT torsinA, as well 
as contribute to the mislocalization of ΔE torsinA in the NE.  LULL1 behavior is 
inconsistent with a AAA+ substrate protein, and suggests that LULL1 may instead 
facilitate torsinA AAA+ activity in the INM.   
How does LULL1 function mechanistically affect torsinA?  Our work has established 
that LULL1 is functional in the ER, and if correct, LULL1 is the first example of an ER 
localized protein that promotes another ER localized protein to localize in the INM.  This 
question can be broken down to a ‘targeting’ mechanistic model versus a ‘binding’ 
model, shown in Figure 6.1.  We propose that LULL1 could modify torsinA so that it can 
reach the INM, or LULL1 may alter the conformation of torsinA to promote binding to 
another INM localized partner, most likely the LINC complex component SUN1 (13).  
Figure 6.1A depicts the ‘targeting’ model, where torsinA is present in the bulk ER, and 
cannot access the INM until LULL1 performs an ER-localized function.  On the other 
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hand, Figure 6.1B shows the ‘binding’ model, where torsinA is present in the bulk ER 
and the INM, but is only retained in the INM when it interacts with an INM localized 
partner, which we hypothesize is LINC complex component SUN1.  Previous work can 
support either of the two models.  For example, WT	  torsinA	  forms	  a	  large	  oligomer	  in	  the	  bulk	  ER	  (14),	  so	  LULL1	  activity	  could	  be	  required	  to	  shift	  torsinA	  from	  a	  large,	  bulky	  complex	  to	  a	  monomer	  that	  can	  access	  the	  INM,	  which	  supports	  the	  ‘targeting’	  model.	  	  However,	  other	  studies	  have	  shown	  that	  both	  LULL1	  and	  SUN1	  are	  required	  for	  WT	  and	  ΔE	  torsinA	  NE	  concentration,	  which	  suggests	  that	  a	  second,	  INM	  localized	  partner	  is	  required	  for	  NE	  accumulation,	  and	  supports	  the	  ‘binding’	  mechanism.	  	  To differentiate between these possibilities, we could use a rapamycin-
based INM targeting strategy, similar to experiments described previously (21).  This 
strategy would involve a nucleus-localized rapamycin binding “trap” protein construct, 
and ΔE torsinA fused to a rapamycin binding domain.  The ΔE torsinA fusion construct 
would initially be localized to the bulk ER, but treatment with rapamycin would result in 
interaction between the nucleus restricted ‘trap’ construct and the rapamycin binding 
domain on ΔE torsinA, leading to concentration of the torsinA construct at the INM.  
This rapamycin-trap construct would allow us to test directly whether torsinA can access 
the INM without LULL1 present.  Thus, if the ΔE torsinA fusion protein is localized to 
the INM, even when LULL1 is not overexpressed, LULL1 is not needed for ‘movement’ 
of torsinA into the INM, and likely promotes interaction with an INM-localized torsinA 
partner.   
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Interestingly, although WT torsinA is intrinsically localized to the bulk ER, and ΔE 
torsinA appears variably localized in different in vitro cell lines, ATP-stabilized mutant 
E171Q torsinA is consistently present at the NE in every in vitro cell line we have tested.  
This suggests that E171Q torsinA is able to bypass the requirement for LULL1 to reach 
the NE.  E171Q torsinA is a Walker B box mutant, and is unable to hydrolyze ATP, so it 
is ‘locked’ in an ATP-bound conformation.  Thus, it is attractive to hypothesize that 
ATP-bound torsinA adopts a conformation that allows access to the INM.  LULL1 might 
act as an exchange-factor that facilitates ATP binding, and leads to a conformational 
change that promotes access to the INM.   
Ultimately, fully elucidating the mechanism of torsinA will yield important insights for 
the development of new primary dystonia therapeutics.  Although a great deal of research 
has focused on torsinA, there are still many questions that must be addressed in the 
future.  Our work has laid a foundation for future studies in the LULL1 mediated INM 
mislocalization of disease-related ΔE torsinA, and set up a preliminary in vitro system 
that can be used to  test the torsinA AAA+ biochemical function.  
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Figure 6.1: Two models for the mechanism of LULL1 activity.   
A. Schematic showing the “targeting” model, where torsinA (orange) is present in the 
bulk ER system, but cannot access the INM subdomain of the NE without LULL1 
activity.  B. Schematic depicting the “binding” model, where torsinA (orange) is present 
in the bulk ER, but can access the INM subdomain of the NE.  However, torsinA is not 
retained at the INM without LULL1 activity, which promotes interaction with an INM 
localized partner, which we propose is LINC complex component SUN1.   
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